# CGT-Daily-News

## ğŸ§¬ æœ€æ–° CGT è¡Œä¸šåŠ¨æ€

æ›´æ–°æ—¶é—´: 2026-01-16 16:39:23

- **ä¸ºä»€ä¹ˆåŸºå› å’Œç»†èƒç–—æ³•åœ¨ FDA åœæ»ä¸å‰** <br> <small>*Why gene and cell therapies are stalling at the FDA* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMilgFBVV95cUxNVjF2blV4algzUGtlTVgzRzBnUmdoLTBXcEtjQmVzSGppSWZyUXlQLUl5MXdKaF9uNDJUTi00cC14eUowMmRMd3kxMHVHZlNoN2R5VTI5ZEdlSE9PV2hqZDk5UnVrbkFReWZVNl9CbW5SY05IejJHUXhfX1lLZ1lhZGItNEExX2NpNzJjajk3Zzdxc1RlYWc?oc=5)</small>
- **æ½œåœ¨çš„â€œçªç ´æ€§â€ FDA åŸºå› æ²»ç–—é€”å¾„ç•™ä¸‹äº†æœªè§£å†³çš„å…³é”®é—®é¢˜** <br> <small>*Potentially â€œgroundbreakingâ€ FDA gene therapy pathway leaves key issues unresolved* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMixwFBVV95cUxNa3Z6eTFkbTJNUFpSeC1NaFJzcG9LVG5KMTBjTkJtVl9IRXBsWWlJT2JjWWdtZWh1QTUxbXNhc0dfazdFRzloZmRZWlVOMGpWcm5WSXVjNmZudVZlVEJDNzY5ZTNoLTM2ZUJCZEozQmxOdVFpRGdGN3dEN0RXaFVjOFpQT0h5cmFUWjlDNkNYRUJGMFhMMU0xUUpnVllPakdDcldJZ2szNHZ6NGFXUkYyMmN2bzVsaVBNbkI3WHJxZi1qZFo0dlhz?oc=5)</small>
- **æ¯å‘¨ç»†èƒæ²»ç–—ï¼šå„¿ç§‘ä¸­æ¢ç¥ç»ç³»ç»Ÿç–¾ç—…åŸºå› æ²»ç–—çš„ IND å®¡æ‰¹** <br> <small>*Cell therapy weekly: IND clearance for pediatric central nervous system disease gene therapy* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMiugFBVV95cUxQSXpMZUozTzZ4Vzk4TER2cXowYVRDYnRheUR3aGF5ZGI3M1BqN3ZWU2Q2LWJjUGNPczVqcFFlaWk4MmdPNDNXdkowNjViblpVeVpmZmVmak1lUHZyd1pnR2NkTmZ2OXc5SDA3a0dfV1I3R0VxbDFJOTBPSC1FQmdtWS1ZTVVBeEZYYmFLck0teFFmYnhFd0xRSmpqZVUtanBZNjZnZFF3YmM4RmZyV0JHdGE1cUFaNEJRTFE?oc=5)</small>
- **FDA æ‰¹å‡† Opus Genetics çš„ OPGx-BEST1 åŸºå› ç–—æ³•æ²»ç–—é—ä¼ æ€§è§†ç½‘è†œç–¾ç—…çš„ IND** <br> <small>*FDA clears IND for Opus Geneticsâ€™ OPGx-BEST1 gene therapy for inherited retinal disease* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMixAFBVV95cUxPdENlV3pOUW0wTVdNTjVZbHE1ZVZmR0VlWmxBQnBtTV9nWjdfX2xIUU13b2ZMR2dWYW9YSlpFQV9pNjNUUjdFcHZNaW1sNElYb3BCN0xEOFhoSmRpdFBhMVFWb2RXN3BXM3BPT2tlY1NyYS1kcHNRYkl4QjRtSEhCeTB4SHE2ODk1VDFzd2pULUE1d3VQQUFYOEhZcTFiUEY0bG8zR3NLVmcycmRnRDVCbUU2MUk1MndOYm9rZklhaVQ5aWRL?oc=5)</small>
- **FDA æ‰¹å‡†ä¸­è°‹åŒ»è¯ RP å…‰é—ä¼ å­¦åŸºå› ç–—æ³•çš„ IND** <br> <small>*FDA clears Zhongmou Therapeutics' IND for RP optogenetic gene therapy* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMivgFBVV95cUxQOUZKcVVVMlQ1N0licFpwTmQ2YUlvczVtQlFvNjRmZmY5NDhXMDZHbkhNNm1HV2FnYTA0Y0IzZ0lFb0dLNE11WHI2Qzd5T3pjMm44SVA5bjkwVWRPcE1WdTJQQ0xUODh5Mml6ajB5a09iMU8teTk0SW45WGpnMnZYRldFd211STM2NTlUOVBPb2ZqdG5QRHFqWm1JelB0SFhMWlJoVVlVRHJXR1gycW5PRFEyQmdWcEZOT0x6dnRR?oc=5)</small>
- **FDA æ‰¹å‡† Capsida Biotherapeutics CAP-003 åŸºå› ç–—æ³•** <br> <small>*FDA clears Capsida Biotherapeutics CAP-003 gene therapy* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMilgFBVV95cUxOVjhPNzdIZDNBc1ZTbXRzVEdGWDE0bXJHaG5mZ3NaOGtFWGhiZWlEemtNZU5yWmZtQnVTV0djamNDVUNndlFrMDd4OVRmTDMyVmRjNXdJQm5fVjlzNnZTSjgwTkhlLW5BbEQ0MW5mZ21zS25iRnMxMGZ0alZaR0QtWGxadm1RR0k1MzlTMFJyTjRCa19hSUE?oc=5)</small>
- **Verve è·å¾— FDA æ‰¹å‡†å°†ç¢±åŸºç¼–è¾‘è¯•éªŒæ‰©å±•åˆ°ç¾å›½** <br> <small>*Verve gets FDA green light to expand base editing trial into US* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMijwFBVV95cUxOVUZCQ2pBbHRXVXdJOXdXODkxYWpQbmw3NmlhZGRYWlJiQkZRTjZLeFJHTHNKaGlFR3ZPNWRxOHhpVzNmemdmMV9YenkyZDB0N0NGSW9yTkVidnI4WDJGUTJieHhhODZENzJTTXdEeGtnNmR6dGhNMnRTbnhCcGt2UUw0dVB4YnAxUnZhWFNpdw?oc=5)</small>
- **FDA æ‰¹å‡† Ocugen è¿›è¡Œ Stargardt åŸºå› ç–—æ³•çš„ 2/3 æœŸè¯•éªŒ** <br> <small>*FDA clears Ocugen for phase 2/3 trial on Stargardt gene therapy* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMitwFBVV95cUxPMWcwT1VxUlk3LUUzQjRLc2RtX0EwZ3pNZmVmbDJDRV81STJHc21CV1hsaWsxVEJkaWxDS2NzRnNNa3RNTkpXbkRlVXlvdnpCTHNqRWZJc3U3VUlvUlNZa3ViWmkyUlZyR2hDTFV1dEVXdEp4NDRLazNLa0l5cGZPYlU4YWpXWWh4WGJHZm1JcUNfcDVGWF9pS3MzdDQ4WGRJd2poRzZzREQ5NU16ZnhETy1oTEhvZVE?oc=5)</small>
- **FDA èµ·è‰äº†ä¸¤é¡¹å…³äºç»†èƒå’ŒåŸºå› æ²»ç–—äº§å“å®‰å…¨æµ‹è¯•çš„æŒ‡å—** <br> <small>*FDA drafts two guidances on safety testing for cell and gene therapy products* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMirwFBVV95cUxPb01YaVUyWHJfWXlvUmVNeFExakkzYzNYYkItR0JXSlcwaXZPSlVQM0pPVWNkMUVqNXFzOGRhMEtrMnVtZ2o2azQxaFA5aDd3RWd4clVGYlVpVzZiZFU5bHg0LXVRTVdsalo1cU5wNE1weWhtUVdRWWtHbTh2TXQyR1hqUVZMak9KVUJpTGdKODBkUC1NZ0ZZbjA2TFBMV0F0eF9qMmRVYS1abHE5UVBr?oc=5)</small>
- **VectorBuilder åŠ©åŠ› FDA æ‰¹å‡†ä¸–ç•Œä¸Šç¬¬ä¸€ä¸ªè„å¸¦è¡€è¡ç”ŸåŒç§å¼‚ä½“ CAR-T äº§å“** <br> <small>*VectorBuilder Powers FDA IND Approval of Worldâ€™s First Umbilical Cord Blood-Derived Allogeneic CAR-T Product* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMi9wFBVV95cUxOcEhVOVZuV3pPSjQ1anBQa25xOGVLMXlMb1BXZEVPY2VSdjZkUUxXbEtjWlIxajBmZE0xRUZJR3BacTktcG1qdmtHeXdqU3pzbW1PSFFTYjNKVGVJVGc0RnVlMmJ4dkRqUV9XajdndzNnOTI3UERrU3Bla1QwTFRzYlN5NlF6eWZiTzlXc0tkYy1oUjVYcDlYeXJ6SEloMW91ZWhqVHk3blM0Tk9kM1NzcWptLXhnaS1OT1lFbHh6VnF1RzlDN1EwU012TUJhYjZwUXFrQ24yT25yYlI0aWlVc3RPdW1oZGVKelhLNjljcGo1aTdIVEdz?oc=5)</small>
- **AAVantgarde çš„ Stargardt åŸºå› ç–—æ³• AAVB-039 è·å¾— FDA å¿«é€Ÿé€šé“æŒ‡å®š** <br> <small>*AAVantgardeâ€™s Stargardt Gene Therapy AAVB-039 Garners FDA Fast Track Designation* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMiqwFBVV95cUxQbE41UU5ocVk4RkI3TWQ1RzRtR3laZG9VckFkNHhIUnZxTTUzMnJEbXJZM0lmbldwdEtBN21qOGdLMnRROXYyX29uU3VzUDNrY1RlSUk2X2RmSVEwa0R3dU4zc05scHhmNy1ZUlBCVzhmc3pvSlJNQmhsZVFYMkNaU2NfMHJ0VVk5LXFJb2hLR0lfMWEtV2NVbzZwRHE3bUpNbWxyWmFGODIwZkE?oc=5)</small>
- **FDA æ´»åŠ¨å›é¡¾ï¼š2025 å¹´ 6 æœˆåŒ…æ‹¬æ–°å¹³å°æŒ‡å®šã€IND è®¸å¯ç­‰** <br> <small>*FDA Activity Recap: June 2025 Features New Platform Designation, IND Clearance, and More* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMirwFBVV95cUxOWmdITUpzbHd5VXRJQV9hX0dZV0NIa29oU3ItdTJzNERvTlpCYnB0clg1ci1ra28yQkhTTTY0aHViNHBiQnA4ejRXbDd3RW1XUHh2NXRYZnpudk1VbmdOX3JOWXUyZEYxSENOWVE2UXdaZ1JxTW5XWWFYRXBsR2V3RHZnX29xNklxcy11WDZuMEZXWTdmNFFXMzl5RjY4OEUzbXRsM2J4eWRDeTVqc2dF?oc=5)</small>
- **æ¯å‘¨ç»†èƒæ²»ç–—ï¼šiPSC æ²»ç–— III æœŸè¯•éªŒ IND è·æ‰¹** <br> <small>*Cell therapy weekly: iPSC therapy IND for Phase III trial cleared* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMilgFBVV95cUxOekNBYngtOEdrSGhDYUtqbEtrdHBkOVJWTVpJTVZjQ2ROT3hyOU1UbW9KTGtsOTQzdkczczRwM0x3b2hyVU5xS0xFOWZIYkYwMU1jdU4wMGpFbzB3Qml5UHhwLVNkTDg4TVE5aHJ2aHI5Rzl3UmxPUEE1aU9xLW00Q0wwbENRb3RmeXBVUUF6b3BPR1ZfbFE?oc=5)</small>
- **FDA æ´»åŠ¨å›é¡¾ï¼š2025 å¹´ 1 æœˆä»¥ CRLã€å¤šé¡¹ä¸´åºŠæš‚åœç­‰ä¸ºç‰¹è‰²** <br> <small>*FDA Activity Recap: January 2025 Features CRL, Multiple Clinical Holds, and More* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMipAFBVV95cUxPUnpTaXEyYzdNakZYMjJHTkJLN2JYZ2J6aVY4WGo2NnhjWkgwMHlMRFhjMUxDbUZTUVUteGYzUF94N1JWQnMzUkhNTzk4M3N5NmRDMldRSjRfRzd4bEloXzA3SjJmbzFoRnlDc0NaR19FaW1qZEhLYWx2Z09GMW5DWWxKQjFRUjBETlhKMEhvSmhXb2NKUGNDVGVxWDNQb0VWeHZmOA?oc=5)</small>
- **FDA å¹³å°æŒ‡å®šè®¡åˆ’å¯ä»¥ç®€åŒ–åŸºå› ç¼–è¾‘ç–—æ³•çš„å¸‚åœºä¹‹è·¯** <br> <small>*FDA Platform Designation Program Could Ease Path to Market for Gene-Editing Therapies* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMi1AFBVV95cUxQYzFGU2EzbWtQcTZPdDYxc2Y5YXJZMjVFb0tmZ0NWdElIWVJmdHhtbml5RkRZRDBNck1fdW9teE1PMlA2OTRmMndjaXNVLUNPLWVocGZCM0lMMDBjMHRPUzFLU1ZXcUhsWXgyYmhrQnNQaXc4T1I3anl2LVRHSWdEU2dxRXdPeVBTd05zVHJOMkZObThXQ2V2MXdXUHFlOUYtd0xiUlcyeFc1TXhWODRvNHVMTlNWQUFmcVQxRFI2dnlETmZrMjZXX1prbExuYlFDa3pNOQ?oc=5)</small>
- **æ¯å‘¨ç»†èƒæ²»ç–—ï¼šå¤šå‘æ€§ç¡¬åŒ–ç—‡åŒç‰¹å¼‚æ€§ CAR-T ç–—æ³•çš„ IND å®¡æ‰¹** <br> <small>*Cell therapy weekly: IND clearance for bispecific CAR-T therapy for MS* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMinAFBVV95cUxNQ25sc2tTblNhb2hnV1ZfM29nNkhZNDVhU1Rtb1RzVFZlajh1d3NYT3VYM1d2QjZlY0xqS0hxUzJuSlczZ3RLY2hKdkc3WGZVcFhpRXA2Y1RVaEw0TmhYZmRpS3NiZ0xhTlQtTExVTHQtTlo1dWIwV1RVbTQyeHdadFh3ZVJMYmNNdXVxci13YXhBVVkydmt1VFBTTGU?oc=5)</small>
- **FDA æœ€ç»ˆç¡®å®šç»†èƒå’ŒåŸºå› ç–—æ³•çš„ä¼å¼è¯•éªŒæŒ‡å—** <br> <small>*FDA finalizes umbrella trial guidance for cell and gene therapies* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMisAFBVV95cUxNN2JpNXFBd29RY2wzSXpkS2xOdmxCeGZUREZGVVZ0X1JEaGxZUV9odGVhYjJzdXU2ZGhtMnl6QUdESG5jYWJYX2JHNEhTM2laTENYeWFIaTFSdTlReXVUMUg4QU1LcVE0Y19HSDk4MS1uREwwTU9pb2JnOXBnMU93WVQxVVJvM3kyN0wybDlhazVxb0JzZjYyVXNnRTZUekhaNDY0MkI3S2NYbE1feHFLZw?oc=5)</small>
- **FDA æ¨å‡ºå¹³å°æŠ€æœ¯æŒ‡å—ä»¥ç¼“è§£æœªæ¥çš„ç›‘ç®¡é—®é¢˜** <br> <small>*FDA rolls out platform technology guidance to smooth future regulatory encounters* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMitwFBVV95cUxNRU03YWR1ZS1mZ2t4OXNyY3cyWE5xWGJtRGQ5SG5yLTl5RHA1MllYblNnNjE3Ti1ua3pRRWRTanM5MTh5RTFXODdmTHNvTGNsY0FtbHdkc2tEYlRqVGlxVXFCb21BN2h2U0pUYlRsZ1FLanZkeTNOTVd2aHRfRDY5LVNac3JRTlp2YUxQX0JWdHJ3elVfTlg3LUFzbGl2eW95dUJHcjdWdEZtZHBJUDN2UkdwUUNKQ0k?oc=5)</small>
- **FDA ä¸ºä¸ªæ€§åŒ–ç½•è§ç—…æ²»ç–—å¼€è¾Ÿäº†æ–°çš„å®¡æ‰¹é€”å¾„** <br> <small>*FDA opens up new approval pathway for personalised rare disease treatments* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMiU0FVX3lxTFBCc3dfdjJscThYcndVS3Zral9TQUY3M2VXcnJfVTc5WHVuaXpXWC1fRHM0WHFqQzF2VnFlbklrSE1NQ1haU3RsTWNad29Ua1lnY193?oc=5)</small>
- **FDA ä¸ºå³å°†åˆ°æ¥çš„ç»†èƒå’ŒåŸºå› æ²»ç–—æäº¤ç¹è£åšå¥½å‡†å¤‡** <br> <small>*FDA Braces for Looming Boom in Cell and Gene Therapy Submissions* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMikwFBVV95cUxQTTJnLXVzLWxJdk5HY0lnTHloVTRKandWcDR1el9xWEFfblVBS0kwbHdQcG11SU1YSVJCQlNkWHV4YnN6a1cxTDRzYUtkWTZGMDBCd2FuSGJIS0t2Z0VreGZNTGNsdjhYZ3UwWE1peGNvMUpUaTBlMjdUcmQ0bTR6RGhzLVpRXzBWMnZjSjVuUl9vUDQ?oc=5)</small>
- **Ocugen, Inc. å®£å¸ƒç¾å›½ FDA æ‰¹å‡† IND ä¿®æ­£æ¡ˆï¼Œå¯åŠ¨ OCU400 3 æœŸä¸´åºŠè¯•éªŒâ€”â€”ç¬¬ä¸€ä¸ªè¿›å…¥ 3 æœŸçš„åŸºå› ç–—æ³•ï¼Œå…·æœ‰å¹¿æ³›çš„è§†ç½‘è†œè‰²ç´ å˜æ€§é€‚åº”ç—‡** <br> <small>*Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial â€” First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMiugFBVV95cUxQUWRiWHJCMG1zM25JamRDcXo5OFFveXZUQnNWY2c5bWJqSVdDeDQzblI1ZU5xNk4tS0lYWlZDYVEyVzhiempwSzdqZmEzc184TUlmS005djhsYk00VDRZU2xEcEFwNWFlMllxMHl6cl9ZNnUwRnVRaWVUMW1HMjh2ck9pWTE2Tkx4THI1cnA1LW82M3o2TFpfMk40MmVfZERSVnVRZUxRM01MSGRDeGI4TFlIY0hEVlIzd1E?oc=5)</small>
- **FDA æ–°è®¡åˆ’å¢åŠ äº†æç½•è§ç–¾ç—…æäº¤çš„çµæ´»æ€§** <br> <small>*New FDA Program Adds Flexibility For Ultra-Rare Disease Submissions* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMiqwFBVV95cUxPQ0xBV085WWYxX2tJb1h4WFd3ZTA1cWh0a00zS2hrYTdsY0ZHR21lX2hoaDJQRVJfbjloRUVIbW1xT0ZDdWVFMFJqbmt1ci1RRFdfMHZqQW5MRXRoc3p2aTZvTm94MnY5TW5jTnFXWEJpSENYRk0zMFkwaTk3UkJDZnFNZk1XMnNDa25sUnM2cElmblJyZDREX0Z4aVhJcFFybzQ1NUdoN3lNUms?oc=5)</small>
- **æ¯å‘¨ç»†èƒæ²»ç–—ï¼šå¿ƒè„ç»„ç»‡å†ç”Ÿç»†èƒç–—æ³•è·å¾— III æœŸè¯•éªŒæ‰¹å‡†** <br> <small>*Cell therapy weekly: Heart tissue regeneration cell therapy receives green light for Phase III trial* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMixAFBVV95cUxNdHJadlF3YllPVmNTcEh6ZlNEcFc4aTdpNndpMk8tVWdmeEZBMHFzd21idEVUOFpnOGhPUlJNc01Wci1PNmFaZXR0YjMyUkJTVkk2ekVVQ255R0ZWMjRzMDVFWkUwZlljRzhtZGZyZF9kb202ckpmMVRlbzdxMnZBMjZGbU5DNVo2XzF2NkhsQjFKUlBOaVJ0QVJTRm5MU0p2OWRDeUFpTHlSSFdlcWRuTHVHRm91bWpsemszTmJZd2hRZXA5?oc=5)</small>
- **FDA æœ€ç»ˆç¡®å®š CAR-T äº§å“å’ŒåŸºå› ç»„ç¼–è¾‘äº§å“æŒ‡å—** <br> <small>*FDA Finalizes Sets of Guidelines for Both CAR-T Products and Genome Editing Products* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMingFBVV95cUxQbVhpRWxRNkpRaGRtVWVyU1dUM0VVNDFXSnlvWThjQXJEZXhoY3Z4U19xUDBaSUtnYlRzTnlpSmNGWnJGa1V4TWlQVnJOT1h1QWlVdHBwOUk2NTZyN1JqRUVVa2xHdkdyVXJEZXdlMkF6UUFOVXhubmFzSmpKQkFTYkVmdFhfdnJsdmpNOWRHcF85ZW1GLVZuY0tnekJudw?oc=5)</small>
- **FDA æ‰¹å‡†ç°æˆä½“å†… CAR-T ç–—æ³•æ²»ç–— R/R éª¨é«“ç˜¤çš„ IND** <br> <small>*FDA Clears IND of Off-the-Shelf In Vivo CAR-T Therapy for R/R Myeloma* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMipAFBVV95cUxNLTJtVHZObk9NVnEyWnZUSWpHTEJ3elZWSVhsdVRUbXUtS082Z3BMNUc1RV85TFc4US0yRjNLOTdiRGNvaXJJR2xqMlN4XzgyM0dYSlFzZ1hLbTNUdWpJYXVDVTJXalNTOG81alNNQlgyTXQxYjM2azI4RGVYbXFaRS05Mk9YelpuLVd1Nnh6MzBzS1RuUjA3NHY4a0MtU24yeFJmZQ?oc=5)</small>
- **FDA å‘å¸ƒå…³äºæŠ¥å‘ŠåŸºå› ç–—æ³•ç”Ÿäº§å˜æ›´çš„æŒ‡å—è‰æ¡ˆ** <br> <small>*FDA issues draft guidance on reporting manufacturing changes for gene therapies* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMirwFBVV95cUxOUmNXME9scGNBSU1fbndrczBkOUN5dnlvSWdGajl2TTBIblhybktrTTh1TEREN1VkMndicWtiOExXT183QURrSzRsLWxYMGtrSnk5TGRxOU9oNDg2a0FURDlsakpscndXZVhIR0NzeTgweHk5eTlZeXBMNUtNR2E0QktFY2VfSXRtTVVKWGhNZkpCMjZRWnRTWGNneGtSeGxHWnZPeU1YZmVzN0dueEZ3?oc=5)</small>
- **FDA å‘å¸ƒå…³äºåŒç§å¼‚ä½“ç»†èƒåŒ»ç–—äº§å“çš„æ–°æŒ‡å—è‰æ¡ˆ** <br> <small>*FDA Issues New Draft Guidance on Allogeneic Cell-Based Medical Products* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMitAFBVV95cUxONzdhR0E1d3A0RFVXX1JiWTVOanI0TTBEMjVCZHh6RXowanNFYlZGMFQ0bERLR0NCRm83VWVlXzRpS3V5OXBTV0xua3FSV09iWUgzMW9PZVFJQ2lzRDRZcnlDVUxCR0tLTks4TVNReEJRSUU3eXRLa0xlcThPcXlkamVfN1pRUzhsV3B3ZzVsaURuWVQxME9lNXBMeEdkLVI0MkcxSVotM01GV1ZtLU4tU241MFA?oc=5)</small>
- **FDA æ‰¹å‡† Base Therapeutics çš„ç¢±åŸºç¼–è¾‘ NK ç»†èƒç–—æ³•ï¼Œç”±é‡‘æ–¯ç‘çš„ cGMP sgRNA å’Œ CytoSict å¹³å°æä¾›æ”¯æŒ** <br> <small>*FDA Grants IND Approval to Base Therapeutics' Base-Edited NK Cell Therapy, Powered by GenScript's cGMP sgRNA and CytoSinct Platform* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMikwJBVV95cUxNTHo0azlJT0VXX1Bodm1XZFJ5a0Zwc3FvQTBBakprT3JXei1qZFVaNmNLczZUV0dUTkpPZEY3QUFhbWZZZmN1aGNOZ0JFZ3N1NlZDd1lHYXpVM3NKRnR3R1Z5Zm0xV1lod2poNFYtMnhXMm85OURTUlExN2psaXBRYTBxMTJmUFlDQzh1d1hpaHAzV0NySGdsdUF1RTRFYU9CV2Q1RkF3Mnc2OHFoWEZNOWN1RXVOY0RVM0tGbTdlbENBampCUDBLc1BsYXg0SExLNXZMbWpTY2s3TWJkdGViTFprTlV4dTVmRWJxcWNRRGhUaXVkNFpyY2pMdS1hRGNLTVRPOUxkVXVmcHU3ekwxbUNjTQ?oc=5)</small>
- **FDA æ‰¹å‡† Verismo Therapeutics çš„ CAR-T ç–—æ³• IND** <br> <small>*FDA clears IND for Verismo Therapeuticsâ€™ CAR-T therapy* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMimwFBVV95cUxNMzBHZVRBOW9xOExkTHJCODRIVHVLeWVOc3VmUFZiamZwUW45R3NCcjNaY0hVak4wc0FZZ0NBcjBxTU5kTHNNVTJ2dGhXOVJvZC1lR3pxU3EtSm5tNlNreXZkVGlyR2o4Y1k3d3hpbTNVTU1NOVZtcnFQMlYtYmpZRU1xb0ExY1JmMDFPQlpCdVdEdV9KTzFkdTZvNA?oc=5)</small>
- **FDA æ‰¹å‡† VNX-101 æ²»ç–— CD19+ æ€¥æ€§æ·‹å·´ç»†èƒç™½è¡€ç—…çš„ IND** <br> <small>*FDA Clears IND of VNX-101 in CD19+ Acute Lymphoblastic Leukemia* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMimwFBVV95cUxNaTUwX0NpMThHXzZNRV9pTnBFdEYyT2NreDIwYmIxMXQ1Z2RwazhyLXM2dnFwTEpZa3l1SVdyZzVzVGVoZFJGS2FwRFI4ODRpV21nMm5XcEtxcEZuMVRpLWVfdnVDSEZCeGpMTVJxUnVFdFJ4TlNucEt6Z2dHMDhBN0NQamd6cUc4MS14QnZsNURsYzhwYlExZXI0NA?oc=5)</small>
- **FDA æ‰¹å‡† UB-VV111 åœ¨è¡€æ¶²ç³»ç»Ÿæ¶æ€§è‚¿ç˜¤ä¸­çš„ IND ç”³è¯·** <br> <small>*FDA Clears IND Application of UB-VV111 in Hematologic Malignancies* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMioAFBVV95cUxPanRIbEw0RERGQVRpOTY3ME1aeUw0amduU2RLZnIwb0RrMlVadDZxMVp5X1l2MFFmbmdVNHQ0UE1LVkZQOTZla3Fyb212ZjlENXBlQUZsdnYta2VDc2FkSWM1c0xLYzR0YjcwSEVxWTY2cjhnNmRKUHFPaWpyY2Q4WFIwd1NKNWlfOGFrYlg4TDFWSjVZX1NZS0d5LUpVcVlX?oc=5)</small>
- **BlueRock Therapeutics å®£å¸ƒ FDA æ‰¹å‡† iPSC è¡ç”Ÿç»†èƒç–—æ³• OpCT-001 ç”¨äºæ²»ç–—åŸå‘æ€§å…‰æ„Ÿå—å™¨ç–¾ç—…çš„ IND ç”³è¯·** <br> <small>*BlueRock Therapeutics announces FDA clearance of IND application for investigational iPSC-derived cell therapy OpCT-001 for the treatment of primary photoreceptor diseases* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMirwJBVV95cUxNTDNIZnQ2U3NhRVpuTGwwTm1XWVR5Z1FiYzNmTjZ0bjZ3bUQ2UlVDUVl4WmNrb25jVHFpMEdmVU44Q3BUNF8zUFdnMU5QMHJ5c1dVX1MxdzhOdXRBRm1QaG91VVpHdnlVWGZrUHl4Y0ZnSEZ4VVRtVnY3VF9SQXMxbEFBdm53R0lYZjFoQnh6ZGRhZVgxXzRvTC1wZTVrTTNYYTB4eHRUQm1mN0VfMkZDYW12VXdvTEIxUlkzVG51UHQzczY1M01LQ1pWQ1czQ19JNkJ5NW9hZG83ajFVcmw2cXpaeU9HNzdpVll0ck54SnVZZzR4SlNJb0R4ZWtndVd4RlhUUzRLYmo2ekFCWS1pT2YzYmZOdl9weklUYkx2czI0Z2hDd0xBMFFUcUtXSmc?oc=5)</small>
- **FDA æ‰¹å‡† VIPER-101 æ²»ç–— T ç»†èƒæ·‹å·´ç˜¤çš„ IND** <br> <small>*FDA Clears IND for VIPER-101 in T-Cell Lymphoma* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMihwFBVV95cUxOX2hReXQ4T2hOS21OeWdWZ256dDAwbXpaczNTbThqTkNjamc4MkcwZW1uVHlJamd1MTJTb0ZVcGdxbXd3MFRMNjMtODQ5NmtxRE9jbTFFSmNhNVBJUm9kSmdHcnBPZXNkRlhUekxzNkRXel9RbTQ3VWtOV0dDMkJCdE84c3pQX0U?oc=5)</small>
- **Poseida Therapeutics å®£å¸ƒ FDA æ‰¹å‡† P-CD19CD20-ALLO1 çš„ç ”ç©¶æ€§æ–°è¯ç”³è¯·ï¼ŒP-CD19CD20-ALLO1 æ˜¯ä¸€ç§ç”¨äº B ç»†èƒæ¶æ€§è‚¿ç˜¤çš„åŒç§å¼‚ä½“åŒ CAR-T ç»†èƒç–—æ³•** <br> <small>*Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-CD19CD20-ALLO1, an Allogeneic Dual CAR-T Cell Therapy for B-Cell Malignancies* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMixgJBVV95cUxNOFFBYUxOWFFsaUoycVlUcGpxTmRaRjU5VFB3NHhuQ2hFQWg1dXBFVHBmV0xIWXlpYjNiM0ZHd05TNG0zeUgzTHZrMkZSc0xOb3V6RFlLUWxnU0s2VkFsY2FackZ3NzhnUGJ2dVBpWXdnSjg4RURJdDVWY1JPMTRZQ2NRT0hnNDlmQ2llaDRvSDF1STZLSnpNTXU5NDhPV1FhYU0wM05EOEpqVkF3WGpLc3owbGVTeUtPbGw5bVVoSmp0cjMzMWRHLU0xbUhRZkdzT3BJMVdKZVpaTGpOZDBlck1ISElIcXllX01mYUdpR055WW9POTRiT1FOQndSd3pFdmFmZHRxNVFZUWlqMDQtLXNvQmpod252OE5xNnhfUDVldHR4cmo2Q1ptWHFZdEtkVEQ2a2hCU2pPcWtvUFZadjViWUtVUQ?oc=5)</small>
- **Kelonia Therapeutics å®£å¸ƒ FDA æ‰¹å‡† KLN-1010 çš„ç ”ç©¶æ€§æ–°è¯ (IND) ç”³è¯·ï¼ŒKLN-1010 æ˜¯ä¸€ç§æ²»ç–—å¤å‘å’Œéš¾æ²»æ€§å¤šå‘æ€§éª¨é«“ç˜¤çš„ä½“å†… BCMA CAR-T ç–—æ³•** <br> <small>*Kelonia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for KLN-1010, an in vivo BCMA CAR-T Therapy for Relapsed and Refractory Multiple Myeloma* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMi0wJBVV95cUxOeU1iQkVrV3BfclNNV053M21zSkhuRlI1VzVWdTBWeGg3Qnc0S3V1LTJxMS1wSE5SbHdUMG1xaW56d1ZLNVBTZjBaU3ZkTkQ3YU16UGhrVHA1clJydjAxUnFTR0dBX1ZiT0FzMEFyeHdGTWpfajY5Y3BhYnFoN3FNVmdrclc3X0dZal9rZ0ZQOE1YTERHQmN6NTQxWGRCRHRFYXoxdENlc0x1ZFF3Y3VZaTdZTjkwN1RJeGVENzRlRUdrNzVHUVI1eDZpUnFIOXQycm5wcl9FMC1IOG9RWU5nZ2JIWFNuQVh2SWw3ZkoyQW1DbXRqdmhPV1RrQW5nVW1ycUNDRmVLNGF3cEV6MkprZFk5bXVrYTNXdzNEZmxiOXFVVHNlWXQzdXRER1MtblQ0Unpocjd0OGVYNUFCTjAteUNWX0FsYXBXYmUxbkM4LS0zSFU?oc=5)</small>
- **æœªç»æ‰¹å‡†çš„å¹²ç»†èƒç–—æ³•ä»ç„¶æ˜¯ FDA æ‰§æ³•çš„é¦–è¦ä»»åŠ¡** <br> <small>*Unapproved stem cell therapies remains a top FDA enforcement priority* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMitAFBVV95cUxQRFgyNmx6Y3RxU0d2aGNhUVJ3Wk8wSExpSWxtZERxZ1p1YmVOekdCekcyV0NfQUt6S05aUUhacUFndm85OW1RRGI1Q0prcmFrX3ZOUlFHZjdVbmVKdFRmTnlfMjBoUE9XeUhKODkzbUo4eHJPVUZoa3d3NEdEM1VuS3JDTHlfWDdfVVlrMy05Z1FWbVRsNnNGcFR4TkVHU3pRU191NExtc1ZtVzFHY3U0SndVbjc?oc=5)</small>
- **FDA å‘å¸ƒâ€œN of 1â€åŸºå› ç–—æ³•ä¸´åºŠå»ºè®®æŒ‡å—è‰æ¡ˆ** <br> <small>*FDA Releases Draft Guidance On Clinical Recommendations For "N of 1" Gene Therapies* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMiuwFBVV95cUxQaEJHRVhwai1QUzFGQWlDekczSUJnaWJzQkI4bjVxMHRla1JNRnNCLVZGc2d2dWc1dktVZi1mZGRuaFhScndkWnNuNHUyMzRvRDU3TDgtcEljcENBVTFYTm1uZFNaSlNUZk1kcUNYUzh2UW12b0RDU3V6aEZXdVVjT2gzUWJ6dkM3cFlNX1I2V1NDRVUybEN0bnJGeTdaTUd4c2J3WHo2WkpGMTVUQ2FyeGdKWlFuUWxFeFpB?oc=5)</small>
- **Allogene çš„åŒæ•ˆ CAR T å€™é€‰è¯ç‰© ALLO-329 è·å¾— FDA æ‰¹å‡†è¿›è¡Œè‡ªèº«å…ç–«æ€§ç–¾ç—…è¯•éªŒ** <br> <small>*Allogene's Dual-Acting CAR T Candidate ALLO-329 Gets FDA Green Light for Autoimmune Disease Trial* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMizgFBVV95cUxNWDluRkFxb1dIZnZYM2dlZzFKaDZRalRRbkJvaldNeEFaUWJHd2czenhZdmZJN0pYTTBPVG9QZmNTOFVxNlJCNVNha21WNlpoRWdzY0lWSTl1dHZ4UENEWEE1a1JmMG5RYThlcGQ3VVZEank4SUpYT205TkVLRS1aS05PNWdwYko2djBwUkFOeG82NEduaXUzdTFJOUcyUzJGTzE0eFBOOUtNcTBiblptRHExbC1acW1QRDdnN1ZiMGRvdVFfeW5OaC14ZlJVdw?oc=5)</small>
- **FDA æ‰¹å‡† Prime Medicine é¦–ä¸ª Prime ç¼–è¾‘ç–—æ³•çš„ IND** <br> <small>*FDA Clears Prime Medicineâ€™s IND for First Prime Editing Therapy* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMisgFBVV95cUxPTUY3bFVabFJqVU9SbEdJMXNYc3Q1ME1WQWNOVzI5SU1CNnZ0SGlUT1lQd2JMcTlFUkJJRW11eW5VNVZlREdPSDc3a1l6c2lMNnd6YkRlU3dranlCY2FfRktjQjhJRHZqcHdGdVlNdXg1R0o0UU1JYU83a0pSeVpyckpFTEIxREk5cFBSbUxBYTltMlNVbDlDWlRDS2R0U3RSUmRTLVlqV2xHRVMxTlNNNFNB?oc=5)</small>
- **FDA CAR T ç»†èƒäº§å“æŒ‡å—çš„è¦ç‚¹** <br> <small>*Key Points from the FDAâ€™s Guidance for CAR T-Cell Products* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMiqgFBVV95cUxOOGtJa1lxanNQdEFDVDgwWmxjUDlsUVdjS3ZYNy0xcmt0WkVaLTIxSHdaNUM2VHZRVnRhWmlnb05Gelh3OXo1S2VLRnVTMHdDS3FXdnBlSzhvdndCdFJJcml3WV9XS0ZBSmlRNHpTQ1Q1a09vQXk1OEtuSWV2NnpQY2R1ZXZCU3dJdE1LM1NiUUFLdXVyTjdUWlhQNHYyT2o3ZFE4eGpJblZhQQ?oc=5)</small>
- **ç¾å›½ FDA æ›´æ–°çš„åŸºå› æ²»ç–—è¡Œä¸šæŒ‡å—ä¸»è¦å˜åŒ–å’Œé‡ç‚¹å…³æ³¨é¢†åŸŸ** <br> <small>*Updated US FDA Guidance For The Gene Therapy Industry Key Changes And Areas Of Increased Focus* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMi0gFBVV95cUxPUU1ta3RQVlJFbHJtOEZ3NkNrTDl5c05QNEM3d3Y0NW1hTXBNMTFIZE9kc19nYnVUcTVQYzEwU1hKYnFac2RoSTJqR2hMSTJqRmlfOXdud1lhNXh5SzlkbmtJcTFlQ1N5T2ZudFg4c0kxdEdGa21RSEVmQzJmcWd2cmhDWEJtS0pFWmxhY0EyZUJBWl9tZ1gxMGlCNGZVbGJibldfcDdFNXJuVmh1VXFJUUVHSjg2U0ZjOExTN1dGaUdJMUJSSEdnOU1iRUZjSUZPSEE?oc=5)</small>
- **FDA æ‰¹å‡†äº¨å»·é¡¿ç—…æ²»ç–— VY-HTT01 çš„ IND ç”³è¯·** <br> <small>*FDA Clears IND Application for Huntington Disease Therapy VY-HTT01* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMilgFBVV95cUxNM1RxQWFDZDVWR1ZFZDRmS2xVWXZVVDdrNU1wdXo5YXoyZEJ0akM3UHBFMWZBZFEwdXVwZlY4U3hxaFFpX29sZWJfYmJSS05HXzB3WmFOTnhNaVVicFQ0NWlTVTBNMnloYlEzV0dSQ3h4UzNPQlhScVgydmkxOWNRT19ITDRsb2toanYwc3FjN2JqbzdBZFE?oc=5)</small>
- **FDA æ‰¹å‡†é¦–é¡¹ç ”ç©¶ CRISPR åŸºå› ç¼–è¾‘æ²»ç–—è‰¾æ»‹ç—…æ¯’çš„è¯•éªŒ** <br> <small>*FDA approves first trial investigating CRISPR gene editing as HIV cure* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMiekFVX3lxTE1sM1d5a2xqQTlhS1JiU2hsN0Z5YXc4YWpvR1o3Y0QxZnlLcU5rZEFEYUp3SXV5ZzZmbFB0ZWNVRWhNei1iTnpfVVFoSncyN0RKSWV1N3RQd3VsbjZpNkdubVZEdEs0M21talQxZWtyaTE2bG9UWmo4cnln?oc=5)</small>
- **uBriGene Biosciences ç¥è´ºæˆ˜ç•¥åˆä½œä¼™ä¼´ InnoVec Biotherapeutics è·å¾— FDA æ‰¹å‡† IVB103ï¼ˆä¸€ç§åŸºäº AAV çš„åŸºå› ç–—æ³•ï¼‰çš„ IND** <br> <small>*uBriGene Biosciences Congratulates Strategic Partner InnoVec Biotherapeutics on FDA Clearance of IND for IVB103, an AAV-Based Gene Therapy* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMioAFBVV95cUxPa2dWM3JqbzhyVFp2LXlmbURwSmE0Uk5ONDFERFhiQms2bUNpNWFDblRlY3huNnJ2YXowajdoTmZ6OTU4WWtELTdzU2VxRnFSVlE3cFFXQ3hmU2tpdmFXamR3MjFKOFZHcm5qWTRxeVJXQ1pvQjNXOVp2N2RXWGMxclpJcWN1enhldDhSU01oSUVQTFNMRnN2SG9tc2xSR1Bz?oc=5)</small>
- **FDA æˆäºˆ IPS HEART æ²»ç–—è´å…‹å°”è‚Œè¥å…»ä¸è‰¯ç—‡çš„ GIVI-MPC å¹²ç»†èƒç–—æ³•å­¤å„¿è¯ç§°å·** <br> <small>*FDA Grants Orphan Drug Designation to IPS HEARTâ€™s GIVI-MPC Stem Cell Therapy for Becker Muscular Dystrophy* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMi9AFBVV95cUxNRmJoYjc2M3R2Q1E3SFJ5VlIwVWp5cXdPTk13LUhUT1doa1ZBQ1JORHBhSExmajlTb2tBUnNHNURXZUh1ckZ5ZlVZZjJoWmRwUXk4aEY0NmRjWUl2ZFpKMUh2MmVLX1JvTWI5ZFc4cVB5eVQ5SDBXR3RvVGFtdk5VczZyU1ZBSllmQTJ3bVdRVGdxSG5qcURQdDNWQ210MFdUZUZNcjVkUWNrQ0I0SjdNQTN6UjRUNW9oSEFxOGYzR3M5bHJIX2RDVTRxZTk0cldmSVpzUUp3d0pTWW9zT2kwNmUwazN0UWNSVjB0Wk5hU1h3VFZH?oc=5)</small>
- **Vironexis Biotherapeutics è· FDA æ‰¹å‡†ä¸Šå¸‚** <br> <small>*Vironexis Biotherapeutics Launches with FDA Clearance of* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMiuwJBVV95cUxQSVlrWnlaMThsVjAwb0JjNHZTdkU5NWw4eG4waG42VVNSR2xtUXBKNzRBb19RR0dBR3c5M1ZRMVU1YUQxQ0wwOEhWWXNJZHFaRmxTSF9FeWQ4cURrUTlaQnFMUDhTSko3Yi1mQks4RV9Id1AzdWJWb0s5ek0zWm9DODBoVXVLTDVVMmdmYWNhUUxhOVNNRFZNMXdwcmU2OF9JOVBjX0ZZY1lqRWlhZFlySXVXT0tKNVJoSGlOYktpaUk2WUo2UHNObmRQTWY3VDh3X25SNVZndDZTTkVoY191d29xbzc3Q3ltaVg2WURlQnRQV282OUhTczYxbGQ1cDhYcGtaZ1gweEpNT3RrdzNpbTNKWFpxRDdKaW16RmMxckZqMDFncDNPZzVuZk9yNkh5cjVDWVVEbktiMWc?oc=5)</small>
- **FDA é¢„æµ‹ç»†èƒå’ŒåŸºå› ç–—æ³•å°†å¼ºåŠ²å¢é•¿** <br> <small>*FDA predicts strong boost for cell and gene therapies* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMikgFBVV95cUxOLU45cEd2WnA5ek9qV1BnRDc5dDdPRF9fUkxWc2F2VUFpdGRrbXFuWE1hVUhMMFJzUU5rbUZOUGVFNnV6a2tidHJEQjJkaXQ5ZFdBbUprMDktZVB2VHdtWkFqbWlzdVlrLUgxemh6bEZPS1NTSjFJZTV2NS0wYmdYdEtSNVgtdVRFWDA4eTM1eGVEZw?oc=5)</small>
- **Sangamo å’Œ Bioverativ å®£å¸ƒ FDA æ¥å— ST-400 çš„ IND ç”³è¯· - ä¸€ç§åŸºå› ç¼–è¾‘ç»†èƒç–—æ³•å€™é€‰è¯ç‰© - ç”¨äºæ²»ç–— Î² åœ°ä¸­æµ·è´«è¡€** <br> <small>*Sangamo And Bioverativ Announce FDA Acceptance Of IND Application For ST-400 -- A Gene-Edited Cell Therapy Candidate -- To Treat Beta-Thalassemia* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMiqAJBVV95cUxPcVcydE9pMkcwdlRYODlwaERPeEtmNzVpbFY0X0lGUG9fZDh2V1F4eE9tS1IzdEZsdVVHdVhURndDMmI5TEswRVJxcl80R3NoUGVtVUhjQjdUUVh5UDZSOUtzdWFSUmRUTEhaMnZuNkU2VXNmSTltXzY1V0pYM1RDNnpCZGl2X3JJZ0hYMmE2c2ktRnc0cWZGdzhHSWd3NVlFUDBhdXdtVXpNTkdxVGxtNW1TQllIOTNnc0VXUnlTa0VYUzZ0Zk00aGxzcFdfMjR5QTAzNzFFdkFxU0hzN08ya2dhRnlGQnVwb1BIR0trMEdCQVNOQWI3ZnhsQWNkRlVJV1cybWhlQUFGMzlLMktRQlRtMlZOWmx5Z1VFTXU4V2lLWDhybDlBNA?oc=5)</small>
- **FDA æ¥å— Intellia çš„ CRISPR å’Œ TCR-T ç»†èƒç–—æ³• INDï¼› SantÃ© ä»¥ 2.6 äº¿ç¾å…ƒå®Œæˆç¬¬å››æœŸåŸºé‡‘** <br> <small>*FDA accepts Intellia's IND for CRISPR and TCR-T cell therapy; SantÃ© closes Fund IV at $260M* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMisgFBVV95cUxPbzFFb0FIQjRYeXVYSm9fcFg5cnU0VzdYdWZjOEIwc05HazltVFEwVEZzS2hBQUhfVzFieHJjaVZJVWxCelhQdFFnZFJUaWd2aXlGVE5JSFlTZExYSkh1dW9LMjNCc0pOLUVGdnFVM0IxN19MS2VQSTZ5WWRlbEZEZVBBV2k2QUlrdWNWRm8xRmVnMG15Z0tYWU9YeEtURmNCX2JuZW5VSjU2bXl3V0lBNGp3?oc=5)</small>
- **é¦–å…ˆæ˜¯å®ä½“ç˜¤Car-Tï¼Ÿ | ApexOnco - ä¸´åºŠè¯•éªŒæ–°é—»å’Œåˆ†æ** <br> <small>*A solid tumour Car-T first? | ApexOnco - Clinical Trials news and analysis* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMidEFVX3lxTFBlUWpReWlkdU54ME9lWGI4VVBZcGVoS1Nfc01HU005c0NZeENCT3VkNzVlRVNNUXY5MkJ2NWpTcVBvUDdScHRKU3FyV2R1ZmdFbFpkTTVDSFNVOU5qSVhiMjQzZXBPU1RobGVTRU5mUWx6dWNN?oc=5)</small>
- **æœ€è¿‘çš„æ‰¹å‡†ï¼ŒCAR T ç»†èƒçš„è¿›å±•æ ‡å¿—ç€ç‹¼ç–®æ€§è‚¾ç‚çš„â€œæ¿€åŠ¨äººå¿ƒçš„æ—¶åˆ»â€** <br> <small>*Recent approvals, CAR T-cell advances signal â€˜exciting timeâ€™ in lupus nephritis* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMiwwFBVV95cUxPUHZNMGM4U3h4bWlfWWtMS0RDalFkczctZ05VVFRBWFIxUnNUN2ZibzczRFNPamtrRDVwVFhxR2FIODMzZEdIbUdKOFBhS0xZcS1jTm5IWEF5aUNjUHItdnJfOGxiLWctX2hZYUhWVGhZMUVXYUNRTC1mYUs3MUtLRjNJbHUxS0hFMW9pRzl3UnlPbk10cnNXZUhGaWNlMVVMcmZKeElLRkVrb19NQW1ndV93VFhubHhiUGduM2JkYWQ5Ukk?oc=5)</small>
- **CAR Tç»†èƒæ²»ç–—ä¸´åºŠè¯•éªŒç®¡é“ç»éªŒ** <br> <small>*CAR T-cell Therapy Clinical Trial Pipeline Experiences* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMixwJBVV95cUxQV1JBcWNmYk85cFJyVU9PYzE1c0x3b2RjcW9fN1JUQ1FNc1BRUjNMRkltMTl3cHZCdnpoOHFvQlFCY3BrQ0ZWa1lxQnNCb055NlZyVlcwelZGd1hxRmhCVnBybXdSS1B3eFJZT1JUV0JfWGFEM2Vvc3ZJNzdRdUlPcmR4YkJjSEEyWGhIYm0xZkk0cXJLTzNXeXR3anY5cjA4eEQwbzNVWjUtSWxDdm55Ti0zWFh3TW8zUnlRcmpVTFhQc0NCMmJydTdVUzBYbXdGbGR5R2xPeWNLX3VuV0t6bWduNW1GYnhSYl8zbmFfa2lteDBGTzNtQUlKNHlOczZjYXFISHdpc3dtUm9IY0FCNmQwZ2hPeEhYdTAwaFFwTXlGd2Z4NHdpbUxiZXU1dGM5UjBrVjQ2UTc5QlJkM0NyUVlQWnBQTkU?oc=5)</small>
- **Regeneron è¿›å…¥ T ç»†èƒæ¥åˆå™¨é¢†åŸŸ | ApexOnco - ä¸´åºŠè¯•éªŒæ–°é—»å’Œåˆ†æ** <br> <small>*Regeneron enters the T-cell engager arena | ApexOnco - Clinical Trials news and analysis* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMihgFBVV95cUxNSlYtNVFOejV3T2xfSTZFMDA0d1hfbUVURm5WNnluNWJUYWQ2SE9BbnE0Ry1LcXZfOExJalJjUzBJcFdUbHdXdkJBVEpNZ3JVNlQ3cGowWk9oRzhNSmRCZERpNFNaMkpNWEV2dl9MSUdETEhIeG1tUGdNR0w1TkwwV29aWXY5Zw?oc=5)</small>
- **27 å¹´å Precigen è·å¾—æ‰¹å‡† | ApexOnco - ä¸´åºŠè¯•éªŒæ–°é—»å’Œåˆ†æ** <br> <small>*After 27 years Precigen gets an approval | ApexOnco - Clinical Trials news and analysis* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMihgFBVV95cUxNdFZVbmFmODhudW5LM1pGSUxfa243NWZ0Yk9vMDVyclJtLUViREp4ZlFJUDRNZGR2VXlQWWxMN2FTUWxBX1ZyWWlmX3hHWWdfRU5wbUVaQzl6RWJzVXpaNVd6VnM1Q0tsTXljb3hhMW1JUzZBVXE5cENJSktfYnRsNWViM2xvZw?oc=5)</small>
- **ç™Œç»†èƒç–—æ³•ï¼šå…¨çƒä¸´åºŠè¯•éªŒè¶‹åŠ¿å’Œæ–°å…´æ–¹å‘** <br> <small>*Cancer cell therapies: global clinical trial trends and emerging directions* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMiX0FVX3lxTE92dUVLald4U3pMSU1kZWFnR1puWjVPbXpHMzN4bDVpUXg5a2tNUW10dFRQWk5qMkx2dGszcEFzYjFtTm11Q1oxeUl5VktDekVpWFZIUEJrbHNCOWtheUdr?oc=5)</small>
- **Columvi é¿å…äº†æœ€åçš„æƒ…å†µ | ApexOnco - ä¸´åºŠè¯•éªŒæ–°é—»å’Œåˆ†æ** <br> <small>*Columvi avoids its worst-case scenario | ApexOnco - Clinical Trials news and analysis* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMihwFBVV95cUxOSVZDQjFkVk93YXhucTIwS1N0VzNSb2VqZ3Z1elZhQkZfb3RycFItQUVtdkNIWVlaMWdmU3BQOExXTGRqaEVqa1pnckhRTk5tUkZHS3Q1bGRuNVFtYjVxaHFya2wwem4wTkJnbDl3NmpaX2hzMWE0SGtHU2xtRmhESVdlSTdFUmM?oc=5)</small>
- **Crispr çš„ Car-T å…³é”®æ—¶åˆ» | ApexOnco - ä¸´åºŠè¯•éªŒæ–°é—»å’Œåˆ†æ** <br> <small>*Crisprâ€™s Car-T crunch time | ApexOnco - Clinical Trials news and analysis* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMidkFVX3lxTE9xZXcyMmRvc1ZnTUJwTndGdGlkX3NMb05NUWY1THlaZnFxbFVRRVprd0FuLW5HTkk3bnpDRVk5c0JPTEZWOEU5eG9NY05kVHhOd1BNTWdUaDMtazBtSnFWejhDd1VaMVJPcnBHS0N5M3lJSnp1R3c?oc=5)</small>
- **BeOne å…‘ç°å…¶ Imdelltra ç‰ˆç¨ | ApexOnco - ä¸´åºŠè¯•éªŒæ–°é—»å’Œåˆ†æ** <br> <small>*BeOne cashes in its Imdelltra royalty | ApexOnco - Clinical Trials news and analysis* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMiggFBVV95cUxPNnYwVDgyMFRRUjNRejdkODJ5SlVELVdsaFdqck9LX2hJWXRNajJlWm12cE5pSHk0R0dLMGpZZ3lFcTRKaTVVcVFwc2pqU0NGUl83WWVpLUxfeGhmejZEWkZrSUxFc0xXS0lsczRBdHlTYktyN2RacEQ2NFZlMmhMM2V3?oc=5)</small>
- **In vivo Car-T è·å¾—å…³æ³¨ | ApexOnco - ä¸´åºŠè¯•éªŒæ–°é—»å’Œåˆ†æ** <br> <small>*In vivo Car-T gains traction | ApexOnco - Clinical Trials news and analysis* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMidkFVX3lxTFA3Y3lrS1A1Xy1mVXVGWVNhdTgyM3lQWFIyZFBYOEtzby1Da2I0Y2RMYU43VGlNc0xETFV4a0txWjNkWm92RmVrdWthNTVmZXVpeHFiRVFuckpuRWlRLXVveFVVNmtxNUlSZ2txV2ExbGpnM1FnZWc?oc=5)</small>
- **è¯ºå (Novartis) çš„ MorphoSys è´­ä¹°äº‘å½©è‹¥éšè‹¥ç°ApexOnco - ä¸´åºŠè¯•éªŒæ–°é—»å’Œåˆ†æ** <br> <small>*Clouds loom for Novartisâ€™s MorphoSys buy | ApexOnco - Clinical Trials news and analysis* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMigwFBVV95cUxPV0VRUnc0aGUzcnlsc1NyX243TlhzNUt1dW1uZ0wzQl8tQnZINWFPbHJOWDRXNnE4UGQ5Yk96Sy1EdDlKVlJPUWg4S0syVUMyMHgxdzlZeGpfSkYxRmlERzFyLWFNaDhreFIyVl9Ha2tXMjVkU1JuSXNHQkhHaUgxdFBKRQ?oc=5)</small>
- **ç¾å›½ FDA æ‰¹å‡†ç™¾æ—¶ç¾æ–½è´µå®çš„ CAR T ç»†èƒç–—æ³• BreyanziÂ® ç”¨äºæ²»ç–—ç»è¿‡ä¸€ç§æ—¢å¾€æ²»ç–—åå¤å‘æˆ–éš¾æ²»æ€§å¤§ B ç»†èƒæ·‹å·´ç˜¤** <br> <small>*U.S. FDA Approves Bristol Myers Squibbâ€™s CAR T Cell Therapy BreyanziÂ®for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMimAJBVV95cUxQakRoQlVCb1dJWG1YUWdqNFJUWlhGTzA0UzNVWWx1bWQxZ1VjbHRfQWY4eFp4cUQ5dHdHa25RX0sxTkhMR1U4czBjSHYxVE5hckF4WUJhdUhYb0NFZHpCQnNqdURwYTl2Mk00NXZQa2V3cXVmUWZSeERfcE9jVl9ZbDJaVXlUNmdHUGFQdkhVMUZPbEJXY1FVTnVjV2xHX3lGam95cE5BdHpkSzEwckZ5SUVUZDFMdk9DWUd6MHZJdWVFanVNZ0xFaFlhS0FLTkJ0QlJjeVVvbUpaaTRGNXI5UHpNS1pTMVUxRHhZNDR3UU5fYTMzck5vZHdQajBpb01ueHVRT2pMUzVDUS14eUU0ak14UWt2bV9P?oc=5)</small>
- **ASH 2024 â€“ åŠ æ‹‰å¸•æˆˆæ–¯å½»åº•æ”¹å˜ Car-T åˆ¶é€  | ApexOnco - ä¸´åºŠè¯•éªŒæ–°é—»å’Œåˆ†æ** <br> <small>*ASH 2024 â€“ Galapagos turns Car-T manufacturing on its head | ApexOnco - Clinical Trials news and analysis* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMimwFBVV95cUxOdFBnVlpjWmViVHhpd1BFVkptdDRNSm44dHpxZjRnbEJ0TWl1d1BBRVQtYWk1TmNTeTcyd3lMYjlCQzBpN2dkQUs5aS01SjRNRnNBVUllb01TSHRfWlA1T1ZONFhvbEJieU9kaDBNcDNHUW1MUlRXUDFCeGp1eTZPX0xOZVpaVHdpYmlJQVlHOGU2Zm1WSTJRdGt5NA?oc=5)</small>
- **åŠ æ‹‰å¸•æˆˆæ–¯éœ€è¦æ›´å¿«çš„æ±½è½¦é€Ÿåº¦ApexOnco - ä¸´åºŠè¯•éªŒæ–°é—»å’Œåˆ†æ** <br> <small>*Galapagos needs more speed with its Car | ApexOnco - Clinical Trials news and analysis* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMiggFBVV95cUxQUm0wU3NBMGNyYmtKLUxobzRQZkxHU0NXN0piQUpMbGlBaEIzT0wtMENlOFBXNUZuZGFGWlI4LS1PVkgxcldtU2FhTUxFRFZCOENQVXZMaHJrOVhFUmRDdjRNVjNfdFdpeXVJRURvako2VlpyN0lWVEMzajE5ZnNMQnpB?oc=5)</small>
- **Atara ä»æ— æ³•å†²è¿‡ç¾å›½ç»ˆç‚¹çº¿ | ApexOnco - ä¸´åºŠè¯•éªŒæ–°é—»å’Œåˆ†æ** <br> <small>*Atara still can't get across the US finish line | ApexOnco - Clinical Trials news and analysis* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMijAFBVV95cUxPS0diNUJoYkNDM1h4V0pwbHJGNFFOckZZZF9GS2k2YU5qbVBCQlVIazFSV0EzRThGSG9RdjdRMDJXME5SV3VRSGlFLUhNUFZaVjFaSFBGOWhrMnAtN09CaWZvUnRUNGVCTC1iOUlkS2NCeS1zTUVQaVh0d2hnWVZ0S2JZZDhYcTVEN216RQ?oc=5)</small>
- **è±å°” (Lyell) æŒ‘æˆ˜å¼ºç”Ÿ (J&J) å’Œå‰åˆ©å¾· (Gilead) | ApexOnco - ä¸´åºŠè¯•éªŒæ–°é—»å’Œåˆ†æ** <br> <small>*Lyell takes on J&J and Gilead | ApexOnco - Clinical Trials news and analysis* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMidkFVX3lxTE1UOXdBYXJ0Wk9MS0tCUFE1QVNzY3pCUlU3czFvRm50aWlKYzZ3WGcxMVdXakF3UUhDTTZzNlU4YUMxc3UxckJQUHFQM1NwT0FxYzVSUDNYSzEwYzRFc2VpQnFoRGhXMmJBamh0MVdjOTR6UTZ6LXc?oc=5)</small>
- **ç¾å›½ FDA æ‰¹å‡†çš„ç»†èƒå’ŒåŸºå› æ²»ç–—äº§å“æ¸…å• (46)** <br> <small>*List of U.S. FDA Approved Cell and Gene Therapy Products (46)* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMidEFVX3lxTE83V1ZmeTRURkFXSXItZ1c2MTZyb3RlZW5NTURPS0dkaEZkbjhucFFCeDd3V2I2WmFwSnVuNVBjY2ZpNk5wckVXY2IyNmFvMkdGc2h0RU1mZDN3aHhKRDhWUDlKVU03by1GQ2Q0d1JVV3lTVG5i0gF6QVVfeXFMUDZOU1d5MUJqZWFuNDVraG1BTl9VZENtRldrLV9ReEVMM1hnMDRxcVNXemhsWVBHTUxxQnVSVVhCUUt0NFBnb1Y5OU1wVHpyS0JTVHhmLU5BSUdEZ3U1dlRQSUlXZkFLcWFHemVOMEQwclJ4LUlwd0I1WkE?oc=5)</small>
- **ASH 2024 â€“ arlo-cel å…¨é€Ÿå‰è¿› | ApexOnco - ä¸´åºŠè¯•éªŒæ–°é—»å’Œåˆ†æ** <br> <small>*ASH 2024 â€“ full steam ahead for arlo-cel | ApexOnco - Clinical Trials news and analysis* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMiggFBVV95cUxObzFTbkRfMFp4NzVpYnRqa3dxVmlYWld3QVNReWRSQ3U2V1FsdUVZZWVEZVNtRi1relZjbE9KZmlEZ1BrZXZNZzgtdjVySVlNUHJwdWZpN2V2c284ZWN5Q0VkV25EVk50dUdCbk5feXVOcUxOUEFaR0RITm5WZnV1Ry1B?oc=5)</small>
- **ASH 2025 é¢„è§ˆ â€“ å¤šå‘æ€§éª¨é«“ç˜¤ç„¦ç‚¹ | ApexOnco - ä¸´åºŠè¯•éªŒæ–°é—»å’Œåˆ†æ** <br> <small>*ASH 2025 preview â€“ multiple myeloma focus | ApexOnco - Clinical Trials news and analysis* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMiiAFBVV95cUxNbzhTLWVXUFM0dm00QlJxZXI5RHlXTkhOUWpJZWNHMEJ3Zk4wOHlPaDJWSTRxLXV0clU1b3JySkYxankzVnkzc296c1lsY3h5akxKV1hfMUZ1cmlkVUtEckNJWWY5VDFRdzNSQmVUY3o0cHY5bjZIRG9BTVR2M3E1aHNWNkJUdUpD?oc=5)</small>
- **Atara å°† 6000 ä¸‡ç¾å…ƒå˜æˆ 4000 ä¸‡ç¾å…ƒ | ApexOnco - ä¸´åºŠè¯•éªŒæ–°é—»å’Œåˆ†æ** <br> <small>*Atara turns $60m into $40m | ApexOnco - Clinical Trials news and analysis* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMibkFVX3lxTFBla3BYZHhZTmJjck1obnFISTFFZVhxTmFNTW1mNlRjTnlGNGxHNWR1LTVYSm1HMkpSVTRHUVQzRTBVUnRWeWxtWTJ6REJaU3VuZHBWREFOOXZEVC1VQUdLRHVnSTBLMXlIWmZaYTZ3?oc=5)</small>
- **å¼ºç”Ÿå’Œ Legend çš„ CAR-T Carvykti è· FDA æ‰¹å‡†è¿›å…¥éª¨é«“ç˜¤é¢†åŸŸ** <br> <small>*Johnson & Johnson, Legend's CAR-T Carvykti enters myeloma ring with FDA nod* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMiwAFBVV95cUxPSkJMVWY0RXF4a0ZUTy1XZllrNGRSUS1PcHJYVDI3UzVrLUZ4NnpHN3lDTGVHcFJDbUdncDE4N0JxQ1lEcFkzWnNzaFZ5dlNvemxkOEI3bU5ETUlPeHcyNVN5RmZpbWNUbmRpQ0UtcHdpVTVWajlKMGxTWV8tc25JT2VzaU82c3BpTlBpVGl0NnduNk52LVh3aXIxb2V1Q3dBYW4wZ1pZRXB0NXViUXJMMnViS2tPTzZRaS1lX0QxaXE?oc=5)</small>
- **æ­£åœ¨é…é…¿ä¸­ï¼š2024 å¹´ FDA æ‰¹å‡†çš„é¡¶çº§å€™é€‰è¯ç‰©** <br> <small>*In the Pipeline: Top Drug Candidates for FDA Approval in 2024* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMinwFBVV95cUxQRGtqYlkwd2VDLUNRTndfWWcwTlNoNUdlUHYzNlpIYWM3Ynl0QnFjdTdVVkk5cFl3a0tFZENHSHRWRF80SXlsQUcyN0Y1aFNaQkRPZTZVZFNUODVDUU54U3ZWZXhDWWdDVmdzMVpPRmg1SWxTTVE0VEd5aWptUmxpdzhxZ2U3NXJXTGQ3V0lNOXpyQ2NfMUY0NGpTaTYzbG8?oc=5)</small>
- **å¸ƒé‡Œæ–¯æ‰˜å°”åœ¨å¤šå‘æ€§éª¨é«“ç˜¤æ–¹é¢è¿…é€Ÿé‡‡å–å…³é”®ä¸¾æªApexOnco - ä¸´åºŠè¯•éªŒæ–°é—»å’Œåˆ†æ** <br> <small>*Bristol makes a quick pivotal move in multiple myeloma | ApexOnco - Clinical Trials news and analysis* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMilgFBVV95cUxOcDdYVGVjU3p1M2phMlhTMXZXcms0Y2tSVndqY0ZnZW1SU1lqcGJzX1pFV0p2RHlmT29fZnRhOXhpUEhhRGVHQVBJb2xlSWU0T2wzbTVHdnhWemhoYlpHWGpqbE9jV3NtdzZ5eXd0cmtUcFBVMWllRG0yZTlZUkQ2a3pacWx0SGdmdmpvUzdxMWE4M0FlUlE?oc=5)</small>
- **å€¼å¾—å…³æ³¨çš„è¯•éªŒï¼šCasgevy è·å¾—é‡Œç¨‹ç¢‘å¼æ‰¹å‡†åï¼ŒCRISPR ç ”å‘ç®¡çº¿åŠ é€Ÿæ¨è¿›** <br> <small>*Trials to watch: CRISPR pipeline accelerates after milestone Casgevy approval* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMivwFBVV95cUxNQVpPZ25mOXo4RnhvaWJaSExmbnYxY0xlcEQ4aENpXzhtd21sSWp4Uk43UjhfMFloRWFtbFVKQnZqcjdWZFk0bzJfZ0FzMjZoLXhmbWVMNVZ1T1NaVGRRelA0cG1qejBfdTFoWFMtY2FhYXNXUjNyc1o3Mjh3NjZhVVhUMXBvcTBSVmRQcUx0SHRnU21LM3lMU2paQzB3ZnZIbnp3Y01Ec2JpOWtxYkxLMGI4aWJpOXlOMndmV1RUZw?oc=5)</small>
- **æ–½ç»´é›…å®Œæˆé€€å‡ºç»†èƒç–—æ³• | ApexOnco - ä¸´åºŠè¯•éªŒæ–°é—»å’Œåˆ†æ** <br> <small>*Servier completes its retreat from cell therapy | ApexOnco - Clinical Trials news and analysis* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMijAFBVV95cUxNbExwMDE5cElFT09uM3RsOW0ySi1WUWJieWlrcjVSNzdLampKdEVCSkdIWXk5Q3BPWnpVcWpZVDQwal9fZlllb25aejRmRVJWdHR4dEV0UjNNOElsdEh6VGpxcjMtMXI5RnZuSjJJSWVNMlhjWmtCNHVFM242MjRoQUpwVmo5VVQ1Q3VYYg?oc=5)</small>
- **DLBCLï¼šå¿«é€Ÿå‘å±•çš„æ²»ç–—é¢†åŸŸï¼Œç®¡é“æ‹¥æŒ¤** <br> <small>*DLBCL: a rapidly evolving treatment landscape with a crowded pipeline* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMihAFBVV95cUxNN2huQkE0b1pZMlowYVJ1ZXVNQzJDSndFM1ZRUTItNjk5UUVKWDYwRXR6ZG9CUmF1QnJsT1B6OVJkZm5raVdGNE1iZ21nY01NNEhsSmZHVngwVFR3WlJOMkNxT0pYa0dSYkxVX1FWTmFmdnhoQUVtY3o2ckxSTVVmZkhmWnE?oc=5)</small>
- **è°ƒæŸ¥ç»“æœæ˜¾ç¤ºï¼Œä»˜æ¬¾äººçš„å»¶è¯¯æ„å‘³ç€ä¸€äº›æ‚£è€…é”™è¿‡äº† CAR T ç»†èƒæ²»ç–—çš„çª—å£æœŸ** <br> <small>*Delays With Payers Mean Some Patients Miss Window for CAR T-Cell Therapy, Findings Show* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMisgFBVV95cUxPQWxmNWFGQ0E2aTh5c1J0YURlYnQtd203bzZ5S1N4V19hckhvX0hiaUVSWnFLUVFFT1FoVkh6ZFNZeFM3X0tjcGNXM3JXaDh6OHF4aTgwNmg4Mi1PR2NWT1h3aDdMMXlmTkJwSVc3OUQ5MUdZWExQeFlsSERCbXFUX0haY04wQ2Z6a3czY3p4dmdBSkpQQ1BVVTRjNzhuS0t4b0xqbUZZV0E0TkUtOVlCZTdR?oc=5)</small>
- **ç­‰å¾… FDA å¯¹ exa-cel çš„æ‰¹å‡†ï¼ŒCRISPR Tx å‰Šå‡äº† 2 ä¸ªç™Œç—‡é¡¹ç›®å¹¶æ‰©å±•åˆ°è‡ªèº«å…ç–«æ€§ç–¾ç—…** <br> <small>*Awaiting FDA ok for exa-cel, CRISPR Tx cuts 2 cancer programs and expands into autoimmune disease* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMitwFBVV95cUxNQkpfLVpSQk9hRHBNekJrX21POVloUFNKU3l1RzMyNlhKMnM2V1o4OG4weHRtMHNjWERzWHZwZFFfYllhd2Z4NE1QX3ZNVDdha2toR29JVTcwdG5zRzFoRUtOMUoyS2ZRZktDZWFSVHpvd3c1YVdBYTMtWUJDZWtPS2Fib1paSDZfTWV1VENHb0ppRjdJTFdnTVdTTjNIMTVXUUt4T3lfNzMydThVY3ZULUxyRTdQOHM?oc=5)</small>
- **FDA çš„é€Ÿåº¦é˜»æ­¢äº† Agenus çš„ PD-1 æŠ‘åˆ¶å‰‚å·´æ–¯è’‚åˆ©å•æŠ— BLA ç”³è¯·** <br> <small>*FDAâ€™s speed kills Agenusâ€™ BLA application for PD-1 inhibitor balstilimab* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMipgJBVV95cUxQWkE2VVNLMzM0WlFkZzNOekUzVTVJSVhlVUx5Z19tQXJYNk5DNWo2NDd0Zk5INHc4b0RsWk5XTTYtbDdkVjN6X2I4NVBxNHZxTEF4Q1BqU1pYRDRUVTJkYVJHNk9wa1lkQUhfLWpqYVJFWjNWS0huSkZzOWVVZ0Q1eHpDSE5MWTJYcHFOX2xJTEYyX0lVdnhDQTV0bXRCZU8xcHV5TGNuVHlBMnNCZ2h0bGJXTGo1dUtQM3NnWG1hbEZ0M05YclV0MlhCQ3BCal9CWnR5a0xRb1JiWFpJMzhUcnB6LTJrOTg5ZzlvQkVRU0JwSGkza0tQbm81T1RrSnRTVy1ST2FRcmg4R2dQVmNrWng4MF9vZGVQTGVmM3M2NEktOV9sNVE?oc=5)</small>
- **FDA å› ç”Ÿäº§é—®é¢˜æ‹’ç» CAR-T ç–—æ³•åï¼Œç™¾æ—¶ç¾æ–½è´µå®é™·å…¥å›°å¢ƒ** <br> <small>*Bristol Myers Squibb in hot water after FDA rebuffs CAR-T therapy on manufacturing concerns* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMivgFBVV95cUxNN21JcXRVRTNEbG1VZC1YQ3hfSkJGX01lbWtvNVlDX21TekwwQXRabTJpVTZ2ejItbF9jY3dGTldhNW0yMHEwWm1PZVNabUdIM01zdEYtQ0E3bC1FeExNLW9GLTZlVFh6UEcxemk4ZnVyRE9rZW9qQWFKQ01wS3JCTk1LSjVWR25EN2dJenlxWHp0OVRlb0loZ2lyLU1yXzlPcHRDSjE1am5ZOEJUbGtoVmYwNm1yQm5XTVRHZ1dn?oc=5)</small>
- **éšç€éŸ©å›½è€ƒè™‘ Nespesel è·å¾—æ‰¹å‡†å¹¶åˆ é™¤è§‚å¯Ÿåå•ï¼ŒAbClon è‚¡ä»·é£™å‡ - CHOSUNBIZ** <br> <small>*AbClon stock surges as Korea eyes Nespesel approval and watchlist removal - CHOSUNBIZ* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMigAFBVV95cUxPM3ZPdVVSM1ZpVWhiMUVnTHNLNU1wU3hLQVBnTGp5LW03czZObTZIdXRJVFFkdEo4UmFOWGlKRHFaY09WOVdPN0Z1V3h4M2FXOE9qMFRfRnUxTVdINTJmNW5OZ0VqWWJVQzVRWTNIbllYZnBTb0hiX2JLbV9rNmFyY9IBlAFBVV95cUxPeG5Kd3NUZ3NlaEpaS29iUG9iNnNVSmlBWVVHQkh5SThPNTlFX015MUpVVnkxTkJaZW15UHhiZEg3cUNqcWJDbHc1SkxtMXZQLXN6RXJKYkFjQ2pISUN0UlZxbmhkYkdLT2xJMlBvN0NQeVRzS3B3VVZNU0FsQVBzcHVtQkhod0J4bUtDWEFQTGZfRmdw?oc=5)</small>
- **Fierce Biotech ç­¹æ¬¾è¿½è¸ªå™¨ '26ï¼šProxima æ”¶å…¥ 8000 ä¸‡ç¾å…ƒï¼› Kinaset 1.03 äº¿ç¾å…ƒçš„ B è½®èèµ„** <br> <small>*Fierce Biotech Fundraising Tracker '26: Proxima pockets $80M; Kinaset's $103M series B* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMigAFBVV95cUxPWnNIYUVmZkJnUzFkM3dqNFpZaFZRRUdTUWNxb2lMeDY4NklMMGJobEM0NDU3LUQ2ZmRhYjNNaTlRM3N4MzZHOExoV3BGQXk1a1dKNDFHaHlrT0RZX3pYd0g0OVhlNnZobEtEdzBtLTh3ZnRsSWFpbGNjRVVpU1VIMA?oc=5)</small>
- **Waâ€™ed Ventures é¢†æŠ•ç¾å›½ Kure Cells çš„ 1000 ä¸‡ç¾å…ƒé¢„ A è½®èèµ„** <br> <small>*Waâ€™ed Ventures leads $10 million pre-Series A in US-based Kure Cells* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMimAFBVV95cUxPYzA4UEVYOVJqTVN4dnhFY2dfMVBuZHJydHc3RGYtQlZjSThjM1ZfSWhxV2t0a0ZuanV4WkEwd1l6WTRWVUdWOTJsQ3R3cGhtQzB1RzNPMFNFc3dRTl9TMmJvdU01MENJbENSZVlmN0NDdU8wa1MtaXV3RV9HQ2dwZHhKS3g2UHBiN3Nia2RZakcxaFNnZ19JbA?oc=5)</small>
- **è‰¾ä¼¯ç»´ (AbbVie)ã€å†ç”Ÿå…ƒ (Regeneron) å’Œèµ›è¯ºè² (Sanofi) ä¸º Tregs ä¸“å®¶ Zag Bio æä¾› 8000 ä¸‡ç¾å…ƒçš„ A è½®èèµ„** <br> <small>*AbbVie, Regeneron and Sanofi help fund $80M series A round for Tregs specialist Zag Bio* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMirwFBVV95cUxQMnFOVmgzRlBoQzVIbWh0Um42bEdJdExoMklrdS1zXzBacVpLX3RFWEdEWGpUaWt5ektRRm5saHJDeXQzS1pwVl9RbGRtaEZIOUhZT1FzU3BzYmZsLW5xTDhuczlic1FtM3BfeEtYVHJsSWFPVGJ4OVZNYjBPQVJaSnpwTE16VkNqMldaZGR0VjJ2NkJxQjRoUWNuMTRDN2ZpNk5Rb0lYMlpQbUwyalpZ?oc=5)</small>
- **æ„å¤§åˆ©ç”Ÿç‰©æŠ€æœ¯å…¬å¸ AAVantgarde è¿½åŠ  1.41 äº¿ç¾å…ƒ B è½®èèµ„ï¼Œèµ„åŠ©è§†ç½‘è†œç–¾ç—…åŸºå› æ²»ç–—è¯•éªŒ** <br> <small>*Italian biotech AAVantgarde adds $141M series B to fund retinal disease gene therapy trials* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMiwwFBVV95cUxQVmh3MVNIODZLcFh4Q1YzUGRZc2tmam5CUnFUdVhiM0dhWFlpcW11N2JWMVhFQ3pZekJwODF0RkdkOGNCSjd6bUwwdGMtWkpoSS1ZZ3N3N0dkekhibFUwNFR3b3lORmlEZ3EzbktsZlJEWHN6UkFhWWh2cmNNdVhiR09iR2toVUY0Mm0yc2k3TEIyUTNwc1VLclZrWks4TzJMc0RaNnYyMEhuRXhkblhwakd4R1ExcEhEOXdocXFBdU1OZ0k?oc=5)</small>
- **Gallant åœ¨ B è½®èèµ„ä¸­ç­¹é›†äº† 1800 ä¸‡ç¾å…ƒ** <br> <small>*Gallant Raises $18M in Series B Funding* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMigAFBVV95cUxPaEpqRUJadnJDSEZoRWJTV2Nkem5JTXFIQkJJOWZ3Yi13bjBWQlFuZlU3eDEwc3NrbkI3Yk1lcmg0UjBEM3RPNXRONXpyQUN3c1NRWXk0NlF3aWpSVU1QeWRhSWhzV3E3b284c292WE1zMXowU3YtbEhOQThaLWlVWg?oc=5)</small>
- **Ori Biotech ç­¹é›†è¶…è¿‡ 1 äº¿ç¾å…ƒçš„ B ç³»åˆ—èµ„é‡‘ï¼Œæ¨å‡ºåˆ›æ–°çš„ç»†èƒå’ŒåŸºå› æ²»ç–—åˆ¶é€ å¹³å°** <br> <small>*Ori Biotech raises over $100 million in Series B funding to launch innovative cell and gene therapy manufacturing platform* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMiiAJBVV95cUxOYzhXUjh3Mm10aExpb0JSbkdtZGZkVEQ3akpYMG9iMEk3Y3JRSmJ1Y2lRS0dIRGpVMF9CZlIzb1REUjc5cGYtU1RiallOb2VwU2RlNDU0d1ZLYVNmMy1WUE5jSWlOMUN2X093Q3ZkQU1rNS1RR3pNU2Iyd3Q3blFpY0JoeWFUWHA0WlV4bzlzZ1hXYS0ySG15NmVFTkxpeXFhZkxWTzFwTUwtZTBhczZKMWhQYjJub19JdGpWRUhvQjV5OC13alVpVlFaVlB4a0J6bUlKdVR6WjZXV0pRZ1VVT1k0dG1KYVF1M09IdWdodzZnU3ZsdzVlTkZmYUtNOUwzNGlxQmZEYkw?oc=5)</small>
- **ç»†èƒæ²»ç–—å‘¨åˆŠï¼šOri Biotech åœ¨è·å¾—è¶…è¿‡ 1 äº¿ç¾å…ƒçš„ B è½®èèµ„åæ¨å‡ºç»†èƒå’ŒåŸºå› æ²»ç–—å¹³å°** <br> <small>*Cell therapy weekly: Ori Biotech launch cell and gene therapy platform after securing over US$100 million in Series B funding* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMi5AFBVV95cUxQYS1aRmZEQk5hUC1JU3dSOGEtak5DalFqcnVnR1ZmcVprUTQxQ2xOSUMwMnJSRVFxWVoybmw5dkVmdlZvdEREcFVodmdOYXFFcDNfS3MxQzhhVzROODBEOTUwaEhURjdhV2Y4RFR2aWdjM3hLS0ptdzJRZ29MOGY1bWtRZ0NXRGtyUDBNN0RINEdvWGZlWVR6Wk9nUlhBRmlicy1uTGpDeWhjUWd1eVFaUVpkbFdBZWN3bG45V3o1elV5SlZEN1ZYdDJnSjhVT3lqYTVrVzlBUVRrMnV4S0o1QlRlU2U?oc=5)</small>
- **Ori Biotech åœ¨ B è½®èèµ„ä¸­è·å¾— 1 äº¿ç¾å…ƒï¼Œå¸®åŠ©æ¨å‡ºåˆ›æ–°çš„ç»†èƒåˆ¶é€ æŠ€æœ¯** <br> <small>*Ori Biotech reaps $100M in series B round to help launch innovative cell manufacturing tech* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMiwwFBVV95cUxNWkxjdThVSEpvREs5S0lyTDl5U2JjRjhFb1RDTVA3Vm5nemdmVEJYLWJtXzNmLVc1VlRBY01fTDJRZzQ2SzI3TzJaelBkX2twUlMxUWp0VWQxWTlLTFFDYWxMdWE2dUZkQW1JMzllb0Z1b2lsTEp1TVJmME5BLVlzTVpXTjVwa29pYkNSOFAxQjBCd09xVnhTZnBoVm0wQjVjMDhJNTE1ZzRmWHlYelpfVmxtRFY0ZWppN0dRRWJpYm1OVG8?oc=5)</small>
- **ç‘å£«ç”Ÿç‰©æŠ€æœ¯å…¬å¸ CDR Life ä½¿ç”¨ 7600 ä¸‡ç¾å…ƒçš„ A è½®èèµ„ï¼Œä¸º T ç»†èƒå‚ä¸ä¸´åºŠåšå¥½å‡†å¤‡** <br> <small>*Swiss biotech CDR Life uses $76M series A funding round to ready T-cell engagers for clinic* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMixAFBVV95cUxPRXdheHVSZkdUSGZRNUJnVFlrQzRGYndhRW5wcEMzTnE0cUVZMnE3aEF2ZnFzeE5DZ2RIVU05Umx3aDI5VGk0RVAxc09UR3pSd1ZvYVYwekh3d2VQRHFGN2hmRmlKQlZuUUJyQnUzdU83SWlSWGw3MjNmTmpDZzdlVnU0LVlxOUJ4U0ZfMGZNOXJrc1FIMFB0cFlmcmdFZnI3V1FnaXJYbmQ5eTFjTUFHcUYzbVlnMWpxYkJ5ZW80UXBBSmxY?oc=5)</small>
- **AvenCell è·å¾— 1.12 äº¿ç¾å…ƒçš„ B è½®èèµ„ï¼Œä»¥å°†â€œå¯åˆ‡æ¢â€CAR-T åº”ç”¨äºä¸´åºŠ** <br> <small>*AvenCell secures $112M series B to flick 'switchable' CAR-Ts in the clinic* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMioAFBVV95cUxQUFM0WVRPSTdxWlZ1bFI4WWtWRzJmTUNtOG1wbmZqdlRUS1RvYVl6ODV4bzJXanQyNVNqSkFJWWZUaU5FbTBOQUppZ2pvTmhiVktvOGRBWk1wQmc3ZUdLaUZuSk5IRzNFMXJkdDVxaGxVbTJLSVlobkhOYTlWOF96NU1HdmR6ZGRia3FZNjZUZGl2T2paV2Y2S0FjdnRwNnVM?oc=5)</small>
- **å°†å¡‘é€ è¯¥è¡Œä¸šçš„ç”Ÿç‰©æŠ€æœ¯æŠ•èµ„ä¸»é¢˜æ˜¯ä»€ä¹ˆï¼Ÿ** <br> <small>*What are the biotech investment themes that will shape the industry?* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMiygFBVV95cUxNT1d2Nlo4TnpMTzFrTjFmM1F4T1NHVUFPRHNLUGNDNEM4Qm9HYTBFRFp0Qi1wTVFTZzhhRi1WcmdqcG9tcjdjRmRiNFl2RkdXMktCeEVHTmpfdE94RUlETmlxdXZUdFhDd3F6R0QxU2tBUEg0T1JHTkNzekVtVTRGYm5QT1QyODhIbjhDUmRqOGloSWdrMlppTkFzcktMN1BlVzUxVEZJbkxtLWhIR3dEbWNoTUpuV01JWWRDM1g2aG5qWGkySDM5bHJR?oc=5)</small>
- **Seaport Therapeutics è·å¾— 2.25 äº¿ç¾å…ƒèµ„é‡‘ç”¨äºæ–°å‹æŠ‘éƒç—‡è¯ç‰©** <br> <small>*Seaport Therapeutics Secures $225M for New Kind of Depression Drug* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMinwFBVV95cUxNa3h6b1JGcFdjeFR2QUpBWUN1TkowMUZPbHQtQ29aQ1d5QlFQdjBuUm5tZ3N1cnpNeVVTYmxDOVhxMnNrT0NzRkVGZnFITnNrMmJuRE9IZ1JhanVDMU9paGM4TjhRdUVQUEo5OGFPc0hMd0g3NEtyUFpNQXdzVTh5MDE2QTVFN0NKeWJpV2xQWmUwaFRzSTFNRzVhaEFQbmc?oc=5)</small>
- **Ori Biotech ç­¹é›†äº† 3000 ä¸‡ç¾å…ƒçš„ A ç³»åˆ—èèµ„ï¼Œä»¥æ¨è¿›ç»†èƒå’ŒåŸºå› æ²»ç–—åˆ¶é€ çš„åˆ›æ–°** <br> <small>*Ori Biotech Raises $30 Million in Series A Financing to Advance Innovation in Cell and Gene Therapy Manufacturing* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMi_AFBVV95cUxNLTFLLW1iYVptdmU0S0pwSlFSNHFqYVhjbWdQeTlwMkMwNlNRazJ5X2o3dGNqNU9lNDVQSGszaWV0ZkpPQU9OMF9LaGNLbzAtTVFpd0lrRDNNcmZiU2VnbDZFWi1XMXhPeXNXdXdTSW9GVzI1NS04cmEwTEd6eEk3Q2Y1MGlrc0VJZ203anFRdU5iV2xCRXJKWUM3NzBPdjVSd3hkUVNTWEZ1ZGE2a2tWRlFzbURucDUtUExCNHpiZ21OMHJpMERlMmM3TlVPUWtTV3VwcVBJWkRhcGpLVXhYbGFrTkQteXo2QkhmWUdjRXVIVXZFQWFWcFM2Sjk?oc=5)</small>
- **Core Biogenesis åœ¨ A è½®èèµ„ä¸­è·å¾— 1050 ä¸‡ç¾å…ƒèµ„é‡‘ï¼Œç”¨äºå»ºè®¾æ–°çš„æ¤ç‰©ç»†èƒè®¾æ–½** <br> <small>*Core Biogenesis reels in $10.5M in series A to build new plant cell facility* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMiqgFBVV95cUxOYjF6WHF2OUxQdURJWlNlbjV0djRfU01RQVZVOGItZUpscmdqOHRtc1pFc0FQdndxaENMM0dhLU9XeTBxOVNZaTRwN3dReXVNRWdObk9fUUdybEN5RmlBWklvV1hZTlZITnA1MWduS0Jzb1VmMnBVV1JQM3YxOFFRUGUyaHB3NGFwSUNZcUJpVm9KdkllZGlURVE1TmNkbWJJbWVqQ2tFT00zZw?oc=5)</small>
- **è·å…°å¹²ç»†èƒç”Ÿç‰©æŠ€æœ¯ Neuroplast è·å¾— 1000 ä¸‡æ¬§å…ƒï¼ˆ1150 ä¸‡ç¾å…ƒï¼‰çš„ B ç³»åˆ—èµ„é‡‘ï¼Œä»¥è¿›ä¸€æ­¥æ¨è¿›å…¶é’ˆå¯¹åˆ›ä¼¤æ€§è„Šé«“æŸä¼¤çš„å˜é©æ€§å¹²ç»†èƒç–—æ³•** <br> <small>*Dutch stem cell biotech Neuroplast secures â‚¬ 10 million (US$ 11.5 million) in Series B funding to further advance its transformative stem cell therapy for Traumatic Spinal Cord Injury* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMi1gJBVV95cUxQYXpEYWozamJhQ09ueFpjT2YtLUxRZEQtV1ZsRXNGNkFLdFpEcTBUVWpwdkpxbjNBQkJ0VFpTaG1wMDJrcERPdEMxREpiQm1sM3JESE5HT0JIYnFFSmJhcE5VVHJIM1g4RzJxQlRpNXEzTFd6eG5uWFV4dzRRZkI3RzYwZ1RUdndZdHI1cWtYMVZIWTJrNmtuNDRxbmtPNDRvNGVVZEhtRVpQa0xibE5LQUE2ZFFfemFIVzdFbHdjU2VZbjJPUVVTQmhjeW00aUpoMjhIWk5qQjlaU0FsdXBDd0ZDV2EyRk1qQnc1NHkyeWd0ZS1OMFJsWHZlcXg0U0VGN1VnNWIzX3g1LWhhcjk4Z2lGeGtqRkhZSXU0aUk1TXFXaG43T1ZsM3hRY3pOSC1tdHN1R3ExdEJZMFNsY044bThTenE5LU9FN3JMQlFpenBVampNZ0E?oc=5)</small>
- **æ­¦ç”°æ”¯æŒçš„ Ambys å®Œæˆ A è½®èèµ„ï¼Œè¿½åŠ  4700 ä¸‡ç¾å…ƒï¼Œå°†äº 2023 å¹´æµ‹è¯•è‚ç»†èƒç–—æ³•** <br> <small>*Takeda-backed Ambys tops out series A with $47M more to test liver cell therapy in 2023* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMirwFBVV95cUxOVDE2UWwwT29EQTU3ZTAtZmJPdENXMktiZ2pTODBUY1FQeENydDhCSGsxRHRoNjZhTklhMzVBZWhLdjh4WnM2bnppOFk1b3ZLZFBHWndXbWg2UVZ0RF8xLVJxZWp6bzlpMDNhYlQzUHl3Ul9hRTFoM1ZjckNoTXVseU5LX3Z0M2FZdkMwXzVkYl9wUS0tdlJ1WGxSTlNkT01fNUlMRF8zb3M3MTd2XzJj?oc=5)</small>
- **Kenai Therapeutics å®£å¸ƒ 8200 ä¸‡ç¾å…ƒ A ç³»åˆ—èèµ„ï¼Œä»¥æ¨è¿›ä¸‹ä¸€ä»£ç¥ç»ç³»ç»Ÿç–¾ç—…åŒç§å¼‚ä½“ç»†èƒç–—æ³•** <br> <small>*Kenai Therapeutics Announces $82 Million Series A Financing to Advance Next Generation Allogeneic Cell Therapies for Neurological Diseases* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMiowJBVV95cUxObEJZM2hJTGVUbF9IMmJIRG5XV0ZHTk9EZXRMNldoOGxRaTlwMENaQTdaREdrd2xOM3Y4Yno0SGxWOTRUelNjcEN4WnJLek0xSzZVd3B4N0RyRVowbFpTdmNOZ2ZvNVpTY05WT29HSWFqeExJTjBYbVllRGNMUnZsY2ZQNC1KU0htTzcxS2pGSXBmZHVNRGNGM19SV3NyS3hreE40emo0MnZ0enZDdGNjMEsxZjdoQ2U1aURya05fMUdNSmRTdEt4S1UwZTFqNGo2a1JIeWFpNFp5RHpzUjhWMGpYY3hBcEhFdU1QNmRFZks0RHNLLXpjWC1vTTZiM2Z4N0NTeU5LcGFCdEQ3cXZDc3pXbHFoS29IOWl1VmVDN2p6Zjg?oc=5)</small>
- **Abata å¸Œæœ›åœ¨ 9500 ä¸‡ç¾å…ƒçš„ A è½®èèµ„ä¹‹åæ‰¾åˆ° MS ç»†èƒç–—æ³•çš„â€œå®Œç¾å¥‘åˆâ€** <br> <small>*Abata hopes to find â€˜perfect fitâ€™ with MS cell therapy after $95M series A* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMitwFBVV95cUxPWXpIcjdocm5vZk9CQVU4dk9IbGlTU01iREVNNWotaUNsYWtVdWljS1FqbjdyREZBczJLUlE0SVZzQk5xVl9QcE5IX2M5QU1JMXppNlZ1a1hJTHYzREZQQjB3bk9OSHVpUHpLeTFnWWZXSUVoSlBXeDFWckFVS2lfbkdkQWRST19ndUdCQXE0QkRieDBkMXpUZzZnYURiejNEdUxISElsSkdqaTV6Wkd4cm9JcHJDdm8?oc=5)</small>
- **æ‹œè€³æ”¯æŒçš„ç”Ÿç‰©æŠ€æœ¯å…¬å¸è·å¾— 8000 ä¸‡ç¾å…ƒçš„ A è½®èèµ„ï¼Œç”¨äºäººå·¥æ™ºèƒ½ç»†èƒç–—æ³•** <br> <small>*Bayer-Backed Biotech Snags $80M Series A for AI-Powered Cell Therapies* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMixgFBVV95cUxOdVVmVnBVNGltMl9WRUU2VWhfdmYwQ3RNNTg4N1Zkc1ZIeGxkWVZrcU01aDRQamdZUVZwZF9LWXlNaTNMbXBScWVBSVo3d2dRWEFONnhSNWpjU3dSZnVzckJFVmNJSExaX3FXZUVjSjRTd3d4Y0FBQi1yempOY2gtRTJHckV6RFB3WjZKYkNfbjc1NzhrY0Jhb1hwVnZRa3o0NlNWWGs1clF0U0FPT3lyR3NiN1dYanEtREFoRDlBcURZVnVRN0E?oc=5)</small>
- **æ‹œè€³ Leaps é¢†æŠ• Cellino Biotech 8000 ä¸‡ç¾å…ƒ A è½®èèµ„ï¼Œå®ç°å¹²ç»†èƒæ²»ç–—åˆ¶é€ è‡ªåŠ¨åŒ–** <br> <small>*Leaps by Bayer Leads $80M Series A Financing for Cellino Biotech to Autonomize Stem Cell Therapy Manufacturing* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMi_gFBVV95cUxNWGpERHJDdG03cXU2akRSQVZWZUZiX3VwdWFVZ0F4RjlMblQtU0IwaHo1bXk5SXhOTlU5VWdaZzFRNjg2cHVRSk1RemF4M19DZlhJQkdpODVfUFdhVEJsSTlGOEJBeWVKbzNRM0p2VVdITDJ4UjZicDhVVFpjV0JBelpIX3VvalRMcVRQWjg1eGdSdjM5dkdaZFZKQWRVakVXbmhBRkNLVFpnUmFLVjJydzFwTHJ5VUl0aWoyU25TYlJBTTdpOHg1TmxLZ1lWbGh4V1NKVG9Pb0lvVEpBX281RFNsR0ZlaTNMOXVGSXhadzRNLWpfcll3ZTkzeVFxQQ?oc=5)</small>
- **Grit Biotechnology å®£å¸ƒå®Œæˆ 6000 ä¸‡ç¾å…ƒ B è½®èèµ„** <br> <small>*Grit Biotechnology Announces Closing of $60 Million Series B Financing* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMiwwFBVV95cUxOU2FvdTRWWXRmaEQxWmk5QkRsSm9SNVltNVlyWGE3Mk9aaF9qQ0plRmNzd2RUczJaWDhDSXcxM1M3VjBFZzZaWmkxb19LYVN5LVNhN1VJNVVZcW0wZzRwdXRYcU9obHJYdXlKRUp3VlJkUG1ocDBjLUhha09MSEdENjBrZENaY2FEamNxYm5ncjIzSkNYS1VtRmZpNlhKWXh0am1kM2hzbDJxT0Nkdl9KeENRSEdJa2JSSEtBblRDNU5fNnc?oc=5)</small>
- **Mekonos å®Œæˆè¯ºåæ”¯æŒçš„ 2500 ä¸‡ç¾å…ƒ A è½®ç»†èƒå·¥ç¨‹å¹³å°èèµ„** <br> <small>*Mekonos closes Novartis-backed $25M series A for cell engineering platform* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMisAFBVV95cUxOX3EtQ29fa1ltZDdjNVZxbnBTczNGZVFPbDJlbG9kY1NkbVRkdHFCdkNtQmVncUZjRGd6RnJEYVVuTjh3U1NzZkszRWxLdW9oS3gydVpoU3JVbWhKNEw5QWROWDUwTS1veS0zbXNsd2ctZGVZTmRXVnFPSkdUZndkeFd5d3VWdF9KbnhrbnVaeHpXMDc1c2FhLWJwMzJ1ZEJLMFduM1RWOXpPWW94ekhfVw?oc=5)</small>
- **ç”Ÿç‰©æŠ€æœ¯åˆåˆ›å…¬å¸ Mekonos ç­¹é›†äº† 2500 ä¸‡ç¾å…ƒè¶…é¢è®¤è´­èµ„é‡‘ï¼Œä»¥å…‹æœåˆ¶è¯è¡Œä¸šçš„ç»†èƒå’ŒåŸºå› æ²»ç–—äº¤ä»˜éšœç¢** <br> <small>*Biotech Startup Mekonos raises oversubscribed $25 million round to overcome pharma industry's cell & gene therapy delivery hurdles* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMikAJBVV95cUxNVFZSLS0zT1FaQVVFbFZKcW5vSEMwazdnUnRVclE5djJXTG9DRmhZeFhYV0c1TVg0alpnaWk3YU54Uzd4ekE0dTY1czRpYkg4U2NzUGtCb0gtbk1ldGlYR1pISlFaYlM4TmRUOFYydkQwN0pobHR6dU9HQ1BmV0h1djIxU3dhUENMRzUxZEgxak5aQ1V5N3hCd2VIdlFEU0RSMEpYTm9OSHhxVzYtbEo3MGNWNTI3Ukx1cWQtNDRNMWRTZ0xGTkhTcnRCVGdRSlZzVWY3MlFsbG1qci1VV3EyeXJXV1NpSFZCekNaOFI0YTc1Ri1abmZ0UkRkdGFWQ296eWQ3RTg1eklpaUFrLVJNXw?oc=5)</small>
- **Kenai æ‚„ç„¶å´›èµ·ï¼ŒA è½®èèµ„ 8200 ä¸‡ç¾å…ƒï¼Œç›®æ ‡ç„å‡†å¸•é‡‘æ£®ç—…** <br> <small>*Kenai Emerges from Stealth With $82M Series A, Targets Parkinsonâ€™s* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMikwFBVV95cUxNaTZ5QTEyVGJrekZoY3l3TXgwa1doX1BsTDFnbWswcW1kaVpFNFFSaEltbDJtckdJcy1CZGpiUThnWU9QZWRJYTZTZGpzMWJtVU4taHl1ZnlvcDBOOU5DYmRsUk5UUzExV1pXNmlMREFIeFktTW01cFp0czlveERjV1M3YVhXa3FES3hjZWR0LWFUV2s?oc=5)</small>
- **æ³•å›½ç”Ÿç‰©æŠ€æœ¯åˆåˆ›å…¬å¸ TreeFrog Therapeutics ç­¹é›†äº† 6400 ä¸‡æ¬§å…ƒçš„ B è½®èµ„é‡‘ï¼Œä¸ºæ•°ç™¾ä¸‡äººæä¾›å¹²ç»†èƒè¡ç”Ÿçš„ç»†èƒç–—æ³•** <br> <small>*French biotech startup TreeFrog Therapeutics raised â‚¬64 million Series B funding to provide stem cell-derived cell therapies for millions* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMihAJBVV95cUxOaS1tRF9DQVlQalZyV3FNRjZRdC1wWDRWOWYyUTRQdmVHS2lFc1ZZRktXZEZUZUdUZV9Mem1SeUZmbFhkVjktZ3J0eks1TEhJUzdObWNTY215ZjV6eDZKeVdjNDhyVllyamVMYzR6TUczTXVPa3ZGYWxiTzZMR19ZWWJJYjhMNXNTWWRHTFY4VDJuRnJ0VUJ4RW9LLTNsdExmaGotZzB3eXZRV05MSDdGVE9pTHdYLWxxYUhKQ09OVnRvQ2ZDMFp5QmZ0QW9jbnJnaThMS3ZhYmU3cFZQZTVRSkpfZWRHandQODY1TW15dDZMWmxKNV9RQ2pzZmR1aUExSm94dA?oc=5)</small>
- **Aspect Biosystems ç­¹é›† 1.15 äº¿ç¾å…ƒ B ç³»åˆ—èèµ„ä»¥æ¨è¿›ç”Ÿç‰©æ‰“å°ç»„ç»‡æ²»ç–—** <br> <small>*Aspect Biosystems Raises US$115 Million Series B Financing to Advance Bioprinted Tissue Therapeutics* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMi8AFBVV95cUxQU2pTdlczZW1EeDMtc25zTkRZNk9wV0dGcHljeXJXZ2tTdkhjNXdRSGhqSW5PeFdwN1pvZ1hRQU1pdldSUFV2dzFCbERPVUVZM2k3TXI0al9HYy1DUVZWdGp5QXotSXNYVi1QTkZGajJhdEpDNFI4UVdTclhoRVl4b2tXaEt6Y29oNVc2LUJuNGhGMU8xY3l2YVdwMFI2bXZTb21tZmJsY0RVMUhXQWwwNE9KWlZWcnVoYnliYkZIcUNNRDhKcm85Yk5mb3NxdWJjOExfRnJtQ2R0UXlCU2Q4NlJLWFVCSFFUaEdYQ1dLRjA?oc=5)</small>
- **Orna åœ¨ A è½®èèµ„åæ”¶è´­äº† RNA ç”Ÿç‰©æŠ€æœ¯å…¬å¸ ReNAgade** <br> <small>*Orna Buys Competing RNA Biotech ReNAgade After Series A Financing* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMilAFBVV95cUxObExHVkZmY3R4N3NtZkRVNWF3YkxkUHQ1UHpCLXBoY1o4SnFqb1E1SVAwVHF1a0RkY2tkVWRlY1NJdzBaWng1QUJCeFFvb01jZzk4Mm5fMEs1b20yLW8ySW02aXA1S09FZWF1UUhPZkFScjlpUmJKeHZ3NThfQzdtUDVGajhlYXZPMEJlOXpENnhmTWpU?oc=5)</small>
- **SQZ Biotech è·å¾— 1600 ä¸‡ç¾å…ƒ B è½®ç»†èƒæ²»ç–—æŠ€æœ¯èèµ„** <br> <small>*SQZ Biotech lands $16m in Series B for cell therapy tech* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMiggFBVV95cUxQYVVJUXFOMWFGcjNNVWFkZEN1Sm9xeHFfTlpHVC1QZEFXcmZvcldKLWdSTTRyaEFjSVAxNlJQM3VIUExaZ09sS29FdzdsaFhicTA0d3Jac0tvX21ld1NPT2xuRWZuY2xMV2NFcXliMFJXOU5hd25zdmZqdF9nbzcxMFRn?oc=5)</small>
- **Grit Biotechnology å®Œæˆ A+ è½®èèµ„** <br> <small>*Grit Biotechnology Completes Series A+ Financing to* [é˜…è¯»åŸæ–‡](https://news.google.com/rss/articles/CBMiqwJBVV95cUxQS3RtR2ZucEpYSW5VeGd3eFBNYTRmZ3FUTTVqOUlnWWM1aWljOENIYmI5TXI2RFlfY0txc09YajBOUHR0TWI2cTRHd1pRN0JmUUN4OVlVUldnbW13WDNMUHdvLUpCQUxxUlhheWF5cEdxOW43VVZJN2NZZ3VxVWxpZmxIc3kxMVZJTzlxXzNZU3N1MHROcjhpNTF2RjJINlE5VDZJYlNveTdWRWl6dUw3emZZaFdjUV9JeDNqTnJ6S2pmdEt0a0FLenZqZUdjRENJRnB4MElVTEZ1cC1TTWVKcUY4SVppSERxcmJEcW40bE51amRSX1UtWU5WYkk2b21vQTNBSUd1RER3RzFfbVRqcnBFSkF4Y3lkempsM3FIVFlmNXBaWlNLUWZNbw?oc=5)</small>
